[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PopSet](#)[Taxonomy](#)[OMIM](#)[Bc](#)Search for ☒ Limits[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journal Browser](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)[Related Resources](#)[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)☐ 1: Cancer Treat Rev 2001 Aug;27(4):247-55[Related Articles, Books, LinkOut](#)**ELSEVIER SCIENCE
FULL-TEXT ARTICLE**

Dendritic cell vaccines for cancer therapy.

Sprinzi GM, Kacani L, Schrott-Fischer A, Romani N, Thumfart WF.

Department of Otorhinolaryngology, Head and Neck Surgery, University of Innsbruck, Austria. georg.sprinzi@uibk.ac.at

Dendritic cells (DC) are professional antigen-presenting cells whose primary function is the initiation of immune response. Based on the finding that the immune system usually fails to identify and kill cancer cells, DC have been recently used as vaccines for stimulation of tumour-specific immunity. This review focuses on pitfalls related to DC-based vaccination against solid tumours and on improvement of this immunotherapeutic approach for routine treatment of cancer disease. Copyright 2001 Harcourt Publishers Ltd.

Publication Types:

- Review
- Review, Tutorial

PMID: 11545544 [PubMed - indexed for MEDLINE]

[Display](#)[Abstract](#)[Sort](#)[Save](#)[Text](#)[Clip Add](#)[Order](#)[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00



PubMed

Nucleotide

Protein

Genome

Structure

PopSet

Taxonomy

OMIM

Bc

Search PubMed ☒for 

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract ☒Sort ☒

Save

Text

Clip Add

Order

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Cancer Gene Ther 1996 Jul-Aug;3(4):221-9[Related Articles, Books, LinkOut](#)

Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.

Li M, Lonial H, Citarella R, Lindh D, Colina L, Kramer R.

Department of Oncology and Immunology, Wyeth-Ayerst Research, Pearl River, NY 10965, USA.

This study reports the successful introduction into tumor cells of a ribozyme directed against an oncogene using a retroviral gene delivery system. A hammerhead ribozyme that selectively targets and cleaves the activated Ha-ras (V12Ras) oncogene was delivered using a retroviral vector and expressed under the control of a transfer RNA promoter in V12Ras-transformed 3T3 murine fibroblast and rat colon epithelial cells. The expression of V12Ras messenger RNA and V12Ras P21 protein was reduced by up to 100% and 75%, respectively, in cells transduced with functional ribozyme. Reductions in V12Ras expression correlated with the stable expression of the functional ribozyme in vivo and decreased tumorigenicity in nude mice. Ribozyme constructs containing identical antisense flanking regions, but a mutant catalytic center, did not attenuate V12Ras expression or decrease the tumorigenicity of transduced tumor cells. These data support the potential therapeutic role of antioncogene ribozymes.

PMID: 8853546 [PubMed - indexed for MEDLINE]

Display

Abstract ☒Sort ☒

Save


Text

Clip Add

Order

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00



PubMed

Nucleotide

Protein

Genome

Structure

PopSet

Taxonomy

OMIM

Bc

Search PubMed



for



Limits

Preview/Index

History

Clipboard

Details

About Entrez



Abstract



Sort



Text



Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Mutat Res 1988 Jun;199(2):341-51

Related Articles, Books, LinkOut

Transformation of diploid human fibroblasts by transfection with the v-sis, PDGF2/c-sis, or T24 H-ras genes.

Fry DG, Hurlin PJ, Maher VM, McCormick JJ.

Fee Hall, Department of Microbiology, Michigan State University, East Lansing 48824-1316.

Gene transfection techniques have provided powerful methods to examine the roles of cellular and retroviral oncogenes in the transformation process in rodent fibroblasts. However, the use of such techniques with diploid human fibroblasts has been limited. We have developed transfection procedures to reproducibly transfect such cells with oncogenes, and methods for the biological characterization of the transformants. We have shown that the v-sis and T24 H-ras oncogenes, as well as the platelet-derived growth factor gene (PDGF2/c-sis), are capable of inducing a transformed phenotype in normal diploid human fibroblasts, but are not capable of conferring infinite lifespan or making such cells tumorigenic.

PMID: 3287149 [PubMed - indexed for MEDLINE]



Abstract



Sort



Text

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Jun 12 2002 10:20:00

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspcal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 25 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKLIT now produced by FIZ Karlsruhe and has a new update
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXIT no longer available
NEWS 8 Mar 22 TRCBERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/Capius
and USPATFULL
NEWS 10 Mar 28 LIPNST/CHLC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHM no longer available on STN. Use PAPERCHM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BELSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IPICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 19 Jun 03 New e-mail delivery for search results now available
NEWS 20 Jun 10 MEDLINE Reload
NEWS 21 Jun 10 PCTFULL has been reloaded
NEWS 22 Jul 02 FOREG no longer contains STANDARDS file segment

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d.
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.03a(JP).
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002

=> file medline, cancerlit, caplus, uspatfull, biosis, embase, confsci
COST IN U.S. DOLLARS
FULL ESTIMATED COST
ENTRY TOTAL
0.21 0.21

FILE 'MEDLINE' ENTERED AT 09:11:14 ON 11 JUL 2002
FILE 'CANCERLIT' ENTERED AT 09:11:14 ON 11 JUL 2002

FILE 'CAPLUS' ENTERED AT 09:11:14 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:11:14 ON 11 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 09:11:14 ON 11 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 09:11:14 ON 11 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.
FILE 'CONFSCI' ENTERED AT 09:11:14 ON 11 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

=> s immunogen? (s) transgene?
L1 538 IMMUNOGEN? (S) TRANSGENE?

=> s 11 and allogene?
L2 52 L1 AND ALLOGEN?

=> s 12 and promot?
L3 27 L2 AND PROMOT?

=> s 13 not py>1998
'1998' NOT A VALID FIELD CODE
L4 11 L3 NOT PY>1998

=> d 14 1-11

L4 ANSWER 1 OF 11 USPATFULL
AN 1998:138874 USPATFULL
TI Adeno-associated viral (AAV) liposomes and methods related thereto
IN Philip, Ramilla, Redwood City, CA, United States
Lebkowski, Jane, Portola Valley, CA, United States
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)
PI US 5834441 19981110
AT US 1994-305221 19940912 (B)
RUI Continuation-in-part of Ser. No. US 1993-120605, filed on 13 Sep 1993,
now abandoned
DT Utility
FS Granted
LN.CNT 2059

INCL INCLIM: 514/044.000

INCLIS: 424/093.210; 424/450.000; 435/069.100; 435/172.300; 435/320.100;
435/325.000; 536/024.100; 935/022.000; 935/034.000; 935/056.000;
935/060.000; 935/062.000; 935/070.000

NCL NCLM: 514/044.000
NCLIS: 424/093.210; 424/450.000; 435/069.100; 435/320.100; 435/325.000;
435/458.000; 536/024.100

IC [6]
ICM: A01N063-00

ICS: A61K048-00; A61K009-127; C12N005-00
 EXP 514/44; 514/2; 435/320.1; 435/323.1; 435/172.3; 435/240.2; 435/69.1;
 435/325; 424/93.1; 424/93.21; 424/450; 536/24.1; 935/22; 935/34; 935/56;
 935/60; 935/62; 935/70
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 11 USPATFUL
 AN 1998:118845 USPATFUL
 TI Transgenic non-human animals for producing heterologous antibodies
 IN Lomborg, Nils, San Francisco, CA, United States
 PA Key, Robert M., San Francisco, CA, United States
 PA Genpharm International Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5814318 19980929
 AI US 1993-96762 19930722 (8)
 RLI Continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 which is a continuation-in-part of Ser. No. US 1992-90860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility
 PS Granted
 LN CNT 7909
 INCL INCLM: 424/184.100
 NCL INCLM: 800/002.000; 435/172.300; 536/023.100; 536/023.530; 530/387.100
 NCLM: 424/184.100
 NCLM: 435/069.600; 530/387.100; 536/023.100; 536/023.530; 800/006.000
 IC [6]
 ICM: C12N015-00
 ICS: A61K039-00; C07K016-00; C07H021-04
 EXP 800/2; 435/172.3; 424/184.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 11 USPATFUL
 AN 1998:92262 USPATFUL
 TI Transgenic non-human animals for producing heterologous antibodies
 IN Lomborg, Nils, San Francisco, CA, United States
 PA Key, Robert M., San Francisco, CA, United States
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5789650 19980804
 AI US 1992-853408 19920318 (7)
 RLI Continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 563425 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 30 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

PRAI WO 1991-US6185 19910828
 WO 1991-US6185 19910828
 DT Utility
 PS Granted
 LN CNT 5073
 INCL INCLM: 800/002.000
 NCL INCLM: 435/172.300; 530/387.100; 536/026.530; 800/DIG.001; 800/DIG.002;
 NCLM: 800/DIG.004
 NCLM: 800/DIG.000
 NCLM: 530/387.100
 IC [6]
 ICM: C12N015-00

ICS: C07K016-00; C07H019-04
 EXP 800/2; 536/23.52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 11 USPATFUL
 AN 1998:72461 USPATFUL
 TI Transgenic non-human animals capable of producing heterologous antibodies
 IN Lomborg, Nils, Redwood City, CA, United States
 PA Key, Robert M., San Francisco, CA, United States
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5770429 19980623
 AI US 1995-544404 19951010 (8)
 RLI Continuation-in-part of Ser. No. US 1994-352322, filed on 7 Dec 1994, now patented, Pat. No. US 5625126 which is a continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-155301, filed on 15 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993, now patented, Pat. No. US 5661016 which is a continuation-in-part of Ser. No. US 1992-90860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

PRAI WO 1991-US6185 19910828
 WO 1992-US10983 19921217
 WO 1994-US4580 19940425
 DT Utility
 PS Granted
 LN CNT 8550
 INCL INCLM: 435/240.200
 NCL INCLM: 530/387.100; 530/388.100; 530/388.150; 530/388.200; 800/002.000; 800/DIG.001; 424/184.100; 435/240.270; 435/240.260; 435/069.100; 536/023.100; 536/023.530
 NCLM: 435/328.000
 NCLM: 424/184.100; 435/069.100; 435/332.000; 435/343.200; 530/387.100; 530/388.100; 530/388.150; 530/388.200; 536/023.100; 536/023.530; 800/006.000
 IC [6]
 ICM: A61K039-00
 ICS: C12N005-00; C12N015-00; C12P021-06; C07K016-00
 EXP 800/2; 435/172.2; 435/240.77; 424/184.1; 530/350; 530/387.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 11 USPATFUL
 AN 97:76001 USPATFUL
 TI Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
 IN Lomborg, Nils, San Francisco, CA, United States
 PA Key, Robert M., San Francisco, CA, United States
 PA Genpharm International Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5661016 19970826
 AI US 1993-53131 19930426 (8)
 RLI Continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992,

now patented, Pat. No. US 5454806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

MO 1991-US9206185 19910828
 WO 1992-US10983 19921217

DT Utility
 FS Granted
 LN.CNT 5602
 INCL INCLM: 435/172.300
 INCLS: 424/184.100; 435/091.100; 435/172.100; 530/387.100; 536/023.100; 536/023.530; 800/002.000; 935/019.000; 935/089.000; 935/093.000; 935/103.000

NCL NCLM: 435/452.000
 NCLS: 424/184.100; 435/091.100; 530/387.100; 536/023.100; 536/023.530

IC [6]
 ICM: C12N015-00
 ICS: A61K039-00; C12P019-34; C07K016-00
 800/2: 435/172.2; 435/240.2; 530/388.1

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 6 OF 11 USPTAFULL
 97.36385 USPTAFULL

AN Transgenic non-human animals for producing heterologous antibodies
 TI Lomborg, Nils, Redwood City, CA, United States
 IN Kay, Robert M., San Francisco, CA, United States
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5625126 19970429
 AI US 1994-352322 19941207 (8)
 RLI Continuation-in-part of Ser. No. US 1994-209741, filed on 9 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-165699, filed on 10 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-161739, filed on 3 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-155301, filed on 18 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-96762, filed on 22 Jul 1993 which is a continuation-in-part of Ser. No. US 1993-53131, filed on 26 Apr 1993 which is a continuation-in-part of Ser. No. US 1992-990860, filed on 16 Dec 1992, now patented, Pat. No. US 5545806 which is a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun 1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1992-834539, filed on 5 Feb 1992, now patented, Pat. No. US 5633425 which is a continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991, now patented, Pat. No. US 5569825 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility
 FS Granted
 LN.CNT 7534
 INCL INCLM: 800/002.000
 INCLS: 435/172.300; 536/023.100; 536/023.500; 536/023.530; 800/DIG.001; 800/DIG.004

NCL NCLM: 800/018.000
 NCLS: 536/023.100; 536/023.500; 536/023.530

IC [6]
 ICM: C12N015-00
 ICS: C07H021-02; C07H021-04

EXP 800/2: 435/172.3; 435/172.2; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 7 OF 11 USPTAFULL
 97.1394 USPTAFULL

AN Transgenic mice depleted in a mature lymphocytic cell-type
 TI Krangelott, Paulus J. A., Amsterdam, Netherlands
 IN Berns, Antonius J. M., Spairndam, Netherlands
 PA Genpharm International, Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5591669 19970107
 AI US 1995-454034 19950530 (8)
 RLI Continuation of Ser. No. US 1992-919936, filed on 27 Jul 1992, now patented, Pat. No. US 5434340 which is a continuation of Ser. No. US 1988-280218, filed on 5 Dec 1988, now patented, Pat. No. US 5175384

DT Utility
 FS Granted
 LN.CNT 1599
 INCL INCLM: 800/002.000
 INCLS: 800/DIG.001; 435/172.300; 935/111.000

NCL NCLM: 800/011.000
 NCLS: 800/018.000

IC [6]
 ICM: C12N015-00
 800/2: 800/DIG.1; 800/DIG.2; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1; 935/111

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 8 OF 11 USPTAFULL
 96.99376 USPTAFULL

AN Transgenic non-human animals capable of producing heterologous
 TI antibodies of various isotypes
 IN Lomborg, Nils, San Francisco, CA, United States
 PA Kay, Robert M., San Francisco, CA, United States
 PI US 5659825 19961029
 AI US 1991-810279 19911217 (7)
 RLI Continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

DT Utility
 FS Granted
 LN.CNT 3377
 INCL INCLM: 800/002.000
 INCLS: 435/172.300; 435/320.100; 536/023.530; 800/DIG.001

NCL NCLM: 800/018.000
 NCLS: 435/320.100; 536/023.530

IC [6]
 ICM: C12N015-00
 ICS: C07H021-04
 800/2: 536/23.53

EXP CAS INDEXING IS AVAILABLE FOR THIS PATENT.

LA ANSWER 9 OF 11 USPTAFULL
 96.73050 USPTAFULL

AN Transgenic non-human animals for producing heterologous antibodies
 TI Lomborg, Nils, San Francisco, CA, United States
 IN Kay, Robert M., San Francisco, CA, United States
 PA Genpharm International, Inc., Mountain View, CA, United States (U.S. corporation)
 PI US 5545806 19960813
 AI US 1992-990860 19921216 (7)
 RLI Continuation-in-part of Ser. No. US 1991-810279, filed on 17 Dec 1991 And a continuation-in-part of Ser. No. US 1992-904068, filed on 23 Jun

1992 which is a continuation-in-part of Ser. No. US 1992-853408, filed on 18 Mar 1992 which is a continuation-in-part of Ser. No. US 1990-575962, filed on 31 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-574748, filed on 29 Aug 1990, now abandoned

Utility
Granted

LN CNT 4576

INCL INCLM: 800/002.000
INCLM: 800/DIG.001; 800/DIG.004; 536/023.530; 536/023.500; 536/023.100;
424/184.100; 435/172.300; 435/320.100
NCLM: 800/006.000
NCLS: 424/184.100; 435/069.600; 435/320.100; 536/023.100; 536/023.500;
536/023.530; 800/018.000

IC [6]
ICM: C12N015-00
ICS: C07H021-64; A61K039-00
800/2; 424/85.7; 424/184.1; 536/23.53; 435/172.3
EXF 800/2; 424/85.7; 424/184.1; 536/23.53; 435/172.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 11 USPATFULL
AN 95:65107 USPATFULL
TI Transgenic mice depleted in mature T-cells and methods for making
IN Transgenic mice
Krimpenfort, Paulus J. A., Amsterdam, Netherlands
Berns, Antonius J. M., Spaarndam, Netherlands
GenPharm International, Inc., Mountain View, CA, United States (U.S. corporation)
PI US 5434340 19950718
AI US 1992-91936 19920727 (7)
RLI Continuation of Ser. No. US 1988-280218, filed on 5 Dec 1988, now patented, Pat. No. US 5175384
DT Utility
FS Granted
LN CNT 1598

INCL INCLM: 800/002.000
INCLM: 800/DIG.001; 435/172.300; 935/111.000
NCLM: 800/011.000
NCLS: 800/018.000; 800/023.000; 800/025.000

IC [6]
ICM: C12N015-00
800/2; 800/DIG.2; 800/DIG.1; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1;
935/111

EXF 800/2; 800/DIG.2; 800/DIG.1; 800/DIG.3; 435/172.3; 435/320.1; 435/317.1;
935/111

L4 ANSWER 11 OF 11 USPATFULL
AN 92:107045 USPATFULL
TI Transgenic mice depleted in mature T-cells and methods for making
IN Transgenic mice
Krimpenfort, Paulus J. A., Amsterdam, Netherlands
Berns, Antonius J. M., Spaarndam, Netherlands
GenPharm International, Mountain View, CA, United States (U.S. corporation)
PI US 5175384 19921229
AI US 1988-280218 19881205 (7)
DT Utility
FS Granted
LN CNT 1517

INCL INCLM: 800/002.000
INCLM: 800/DIG.001; 435/172.300; 935/111.000
NCLM: 800/011.000
NCLS: 800/018.000; 800/023.000

IC [5]
ICM: C12N015-00
435/172.3; 800/2; 800/DIG.1-DIG.3; 935/111

=> d his
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998

=> s 12 and cell? (a) therap?
2 FILES SEARCHED...
L5 6 FILES SEARCHED...
L6 1 L2 AND CELL? (A) THERAP?

=> d 15

L5 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:220521 BIOSIS
DN PREV200200220521
TI Evaluation of a novel suicide gene for T cell therapy.
AU Berger, Carolina (1); Blau, C. Anthony; Heimfeld, Shelly; Dalgarno, David; Jackson, Tim; Riddell, Stanley R. (1)
CS (1) Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA USA
SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 694a.
http://www.bloodjournal.org/. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971.

DT Conference
LA English

=> d his
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998
L5 1 S L2 AND CELL? (A) THERAP?

=> s 11 and cell? (A) vaccine
2 FILES SEARCHED...
L6 6 FILES SEARCHED...
L7 12 L1 AND CELL? (A) VACCINE

=> d 16 1-12

L6 ANSWER 1 OF 12 MEDLINE
AN 2001454053 MEDLINE
DN 21390644 Pubmed ID: 11499806
TI Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
AU Wu R S; Koble J J; Besselsen D G; Fong T C; Mack V D; McFarthern J A; Akporiaye E T

CS Department of Microbiology, Hayward, CA 94545, USA.
 NC CA6929-01A (NCI)
 SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (2001 Jul) 50 (5) 229-40.
 Journal code: 8605732. ISSN: 0340-7004.
 CY Germany: Germany, Federal Republic of
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200108
 ED Entered STN: 20010814
 Last Updated on STN: 20010903
 Entered Medline: 20010830

L6 ANSWER 2 OF 12 MEDLINE
 AN 1998073914
 DN 98073914 PubMed ID: 9409449
 TI Construction and characterization of retroviral vectors for interleukin-2 gene therapy.
 AU Fakhrai H; Shawler D L; Van Beveren C; Lin H; Dorigo O; Solomon M J; Gjerst R A; Smith L; Bartholomew R M; Boggiano C A; Gold D P; Sobol R E
 CS Sidney Kimmel Cancer Center, Clemm A. Hewitt Gene Therapy Laboratory, San Diego, California, USA.
 NC AG035 (NIA)
 CA42909 (NCI)
 CA67814 (NCI)
 SO JOURNAL OF IMMUNOTHERAPY, (1997 Nov) 20 (6) 437-48.
 Journal code: 9706083. ISSN: 1524-9557.
 CY United States
 DT Journal: Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199801
 ED Entered STN: 19980130
 Last Updated on STN: 19980130
 Entered Medline: 19980120

L6 ANSWER 3 OF 12 CANCERLIT
 AN 1998073914
 DN 98073914
 TI Construction and characterization of retroviral vectors for interleukin-2 gene therapy.
 AU Fakhrai H; Shawler D L; Van Beveren C; Lin H; Dorigo O; Solomon M J; Gjerst R A; Smith L; Bartholomew R M; Boggiano C A; Gold D P; Sobol R E
 CS Sidney Kimmel Cancer Center, Clemm A. Hewitt Gene Therapy Laboratory, San Diego, California, USA.
 NC AG035 (NIA)
 CA67814 (NCI)
 CA42909 (NCI)
 SO JOURNAL OF IMMUNOTHERAPY, (1997) . Vol. 20, No. 6, pp. 437-48.
 Journal code: CUO.
 DT Journal: Article; (JOURNAL ARTICLE)
 FS MEDL: L; Priority Journals
 LA English
 OS MEDLINE 98073914
 EM 199802

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:84650
 DN 132:16415
 TI Allogeneic cellular immunogens useful as cancer vaccines
 IN Halpern, Michael S.; England, James M.
 PA Allegheny University of the Health Sciences, USA
 SO PCT Int. Appl., 77 pp.
 CODEN: PIXD2

DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200004927	A1	20000203	WO 1999-US15594	19990708
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RM:	CH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GN, GU, HK, IL, IN, JP, KE, KR, KZ, LG, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
AU 994819	A1	20000214	AU 1999-49819	19990708
EP 1100544	A1	20010523	EP 1999-933855	19990708
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI US 1998-93965P	P	19980724		
WO 1999-US15594	W	19990708		
RE. CNT 1				
THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9725860	A1	19970724	WO 1997-US582	19970113
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, IL, IS, JP, KE, KR, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RM:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BU, CF, CG, CI, CM, GN, GU, HK, IL, IN, JP, KE, KR, KZ, LG, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2241952	AA	19970724	CA 1997-2241952	19970113
AU 9716992	A1	19970811	AU 1997-16992	19970113
AU 717356	B2	20000323	EP 1997-902934	19970113
EP 923284	A1	19990623		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001501909	T2	20010213	JP 1997-526124	19970113
US 6365151	B1	20020402	US 1998-167322	19981007
PRAI US 1996-10262P	P	19960119		
WO 1997-US582	W	19970113		
US 1998-101226	B2	19980702		

Lomborg, Nils, Woodside, CA, UNITED STATES
 PI US 2002086014 A1 20020704
 AI US 2001-948939 A1 20010907 (9)
 RLI Continuation-in-part of Ser. No. US 2000-644668, filed on 24 Aug 2000,
 PENDING
 PRAI US 1999-150452P 19990824 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4981
 INCL INCLM: 424/144.100
 INCLM: 424/146.100; 530/388.260
 NCL INCLM: 424/144.100
 NCLS: 424/146.100; 530/388.260
 IC ICM: A61K039-395
 ICS: C07K016-40
 L6 ANSWER 7 OF 12 USPATFULL
 AN 2002:69599 USPATFULL
 TI Cellular immunogens comprising cognate proto-oncogenes
 IN Halpern, Michael S, West Newton, MA, United States
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,
 PI United States (U.S. corporation)
 PI US 6165151 B1 20020402
 AI US 1998-167322 19981007 (9)
 RLI Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,
 now abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on
 13 Jan 1997
 PRAI US 1996-10262P 19960119 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1838
 INCL INCLM: 424/093.210
 INCLM: 424/093.200; 435/325.000; 435/320.100; 514/044.000
 NCL INCLM: 424/093.210
 NCLS: 424/093.200; 435/320.100; 435/325.000; 514/044.000
 IC ICM: A61K035-00
 ICS: A61K048-00; C12N015-85; C12N015-63
 EXF 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2002:220523 BIOSIS
 DN PREV200200220523
 TI A new generation of HSV BAC vectors for preparation of leukemia vaccines.
 AU Thomassen, A. (1); Zibert, A. (1); Quang, H. (1); Glushkova, L. (1);
 Dilloo, D. (1)
 CS (1) Klinik f. Paediatriche Haematologie und Onkologie,
 Universitaetsklinikum Dueseldorf, Dueseldorf Germany
 SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 695a.
 Meeting Info.: 43rd Annual Meeting of the American Society of Hematology,
 Part 1 Orlando, Florida, USA December 07-11, 2001
 ISSN: 0006-4971.
 DT Conference
 LA English
 L6 ANSWER 9 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:419136 BIOSIS
 DN PREV200100419136
 TI Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene
 transfer on the tumorigenicity of a poorly immunogenic metastatic mammary

carcinoma.
 AU Wu, Rita S.; Koble, James J.; Besselsen, David G.; Fong, Tim C.; Mack,
 Vivian D.; McEarchern, Julie A.; Akporiaye, Emmanuel T. (1)
 CS (1) Department of Microbiology and Immunology, University of Arizona, 1501
 N. Campbell, Tucson, AZ, 85724; akporiaye@u.arizona.edu USA
 SO Cancer Immunology Immunotherapy, (July, 2001) Vol. 50, No. 5, pp. 229-240.
 print.
 ISSN: 0340-7004.
 DT Article
 LA English
 SL English
 L6 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:48328 BIOSIS
 DN PREV199800048328
 TI Construction and characterization of retroviral vectors for interleukin-2
 gene therapy.
 AU Fakhrat, Habib; Shawler, Daniel L. (1); Van Beveren, Charles; Lin, Hong;
 Dorigo, Oliver; Solomon, Michael J.; Gjerset, Ruth A.; Smith, Larry;
 Bartholomew, Richard M.; Bogliano, Cesar A.; Gold, Daniel P.; Sobol,
 Robert E.
 CS (1) Sidney Kimmel Cancer Cent., 3099 Science Park Rd., San Diego, CA 92121
 SO Journal of Immunotherapy, (Nov., 1997) Vol. 20, No. 6, pp. 437-448.
 DT Article
 LA English
 L6 ANSWER 11 OF 12 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 2001259161 EMBASE
 TI Comparative analysis of IFN-gamma, B7.1 and antisense TGF-beta, gene
 transfer on the tumorigenicity of a poorly immunogenic metastatic mammary
 carcinoma.
 AU Wu R.S.; Koble J.J.; Besselsen D.G.; Fong T.C.; Mack V.D.; McEarchern
 J.A.; Akporiaye E.T.
 CS E.T. Akporiaye, University of Arizona, Department of Microbiology, 1501 N.
 Campbell, Tucson, AZ 85724, United States; akporiaye@u.arizona.edu
 SO Cancer Immunology, Immunotherapy, (2001) 50/5 (229-240).
 Refs: 88
 ISSN: 0340-7004 CODEN: CIIMDN
 CY Germany
 DT Journal: Article
 FS 016 Cancer
 022 Human Genetics
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA English
 SL English
 L6 ANSWER 12 OF 12 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 97380111 EMBASE
 DN 1997380111
 TI Construction and characterization of retroviral vectors for interleukin-2
 gene therapy.
 AU Fakhrat H.; Shawler D.L.; Van Beveren C.; Lin H.; Dorigo O.; Solomon M.J.;
 Gjerset R.A.; Smith L.; Bartholomew R.M.; Bogliano C.A.; Gold D.P.; Sobol
 R.E.
 CS Dr. D.L. Shawler, Sidney Kimmel Cancer Center, 3099 Science Park Rd, San
 Diego, CA 92121, United States
 SO Journal of Immunotherapy, (1997) 20/6 (437-448).
 Refs: 34
 ISSN: 1053-8550 CODEN: JOIME7
 CY United States
 DT Journal: Article
 FS 004 Microbiology

016 Cancer
026 Immunology, Serology and Transplantation
LA English
SL English

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998
L5 1 S L2 AND CELL? (A) THERAP?
L6 12 S L1 AND CELL? (A) VACCINE

=> s l1 and fibroblast
L7 58 L1 AND FIBROBLAST

=> s l7 and administrat
MISSING TERM AFTER ADMINSTRAT

Operators must be followed by a search term, L-number, or query name.

=>

=>

=>

=>

=>

=>

=>

YOU HAVE RECEIVED 8 CONSECUTIVE ARROW PROMPTS (=>)
The arrow (=>) is the system prompt, where you enter a command. For an explanation of system commands, files, formats, etc., enter "HELP" and the name of the item you want explained at an arrow prompt (=>). Enter "HELP COMMANDS" for a list of commands that can be used in this file. Enter "HELP MESSAGES" for a list of online explanations that are available. The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message. Enter "HELP" or "?" at a prompt to see an explanation of the options. After an error message, enter "HELP" or "?" at the next prompt and you will receive a more detailed explanation of the error and how to correct it.

Automatic help is also available. When AUHELP is 'ON', you will automatically receive help following an error message. For more information on AUHELP, enter "HELP SET AUHELP" at an arrow prompt (=>).

Users who need additional assistance can contact the Help Desk at the nearest STN Service Center. Enter "HELP STN" for information on STN Service Center. You may also choose to contact the database representative for the file you are searching, for more detailed help

on database content and search strategy. For information on how to contact database representatives for the current file, enter "HELP DESK" at an arrow prompt (=>).
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK

=>

=>

=>

=>

=> this
THIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002

L1 538 S IMMUNOGEN? (S) TRANSGENE?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998
L5 1 S L2 AND CELL? (A) THERAP?
L6 12 S L1 AND CELL? (A) VACCINE
L7 58 S L1 AND FIBROBLAST

=> s l7 and administrat
L8 42 L7 AND ADMINSTR?

=> dup rem l8

PROCESSING COMPLETED FOR L8
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)

=> d 19 1-42

L9 ANSWER 1 OF 42 USPATFULL
AN 2002:164809 USPATFULL
TI Inducible eukaryotic expression system that regulates protein translation
IN Leiden, Jeffrey M., Glencoe, IL, UNITED STATES
PI US 2002086427 Brookline, MA, UNITED STATES
AI US 2001-815980 AI 20010322 (9)
PRAI US 2000-191568P 20000323 (60)
DT Utility
FS APPLICATION
LN CNT 2068
INCL INCLM: 435/455.000
NCL NCLM: 435/455.000
IC [7]
ICM: A61K031-70
ICS: C12N015-63

L9 ANSWER 2 OF 42 USPATFULL
AN 2002:157109 USPATFULL
TI Novel chimeric promoters
TI Punnonen, Juhani, Belmont, CA, UNITED STATES
IN Wright, Anne, Woodside, CA, UNITED STATES

PI Semyonov, Andrey, San Francisco, CA, UNITED STATES
 US 2002081708 A1 20020627
 AI US 2001-886942 A1 20010621 (9)
 PRAI US 2000-213829P 20000623 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3342
 INCL INCLM: 435/235.100
 NCL INCLS: 435/005.000; 536/023.720
 NCLM: 435/235.100
 NCLS: 435/005.000; 536/023.720
 IC [7]
 ICM: C120001-70
 ICS: C07H021-04; C12N007-01

 L9 ANSWER 3 OF 42 USPATFULL
 AN 2002:157004 USPATFULL
 TI Databases of regulatory sequences; methods of making and using same
 IN Wolfe, Alan, Orinda, CA, UNITED STATES
 Urnov, Fyodor, Richmond, CA, UNITED STATES
 Guschin, Dmitry, Richmond, CA, UNITED STATES
 Collingwood, Trevor, San Pablo, CA, UNITED STATES
 Li, Xiao-Yong, Richmond, CA, UNITED STATES
 Johnstone, Brian, Benicia, CA, UNITED STATES
 PI US 2002081603 A1 20020627
 AI US 2001-844501 A1 20010427 (9)
 PRAI US 2000-200590P 20000428 (60)
 US 2000-214674P 20000627 (60)
 US 2000-22856P 20000828 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5742
 INCL INCLM: 435/006.000
 NCL INCLS: 435/091.200
 NCLM: 435/006.000
 NCLS: 435/091.200
 IC [7]
 ICM: C120001-68
 ICS: C12P019-34

 L9 ANSWER 4 OF 42 USPATFULL
 AN 2002:148654 USPATFULL
 TI Purified and isolated p1w1 family genes and gene products and methods
 IN using same
 Lin, Hailan, Durham, NC, UNITED STATES
 PI US 2002076797 A1 20020620
 AI US 2001-873737 A1 20010604 (9)
 RLI Continuation-in-part of Ser. No. WO 1999-US28764, filed on 3 Dec 1999,
 UNKNOWN
 PRAI US 1998-110901P 19981204 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 7192
 INCL INCLM: 435/226.000
 NCL INCLS: 435/325.000; 435/006.000; 435/069.100; 435/320.100; 536/023.200
 NCLM: 435/226.000
 NCLS: 435/325.000; 435/006.000; 435/069.100; 435/320.100; 536/023.200
 IC [7]
 ICM: C12N009-64
 ICS: C120001-68; C07H021-04; C12P021-02; C12N005-06

 L9 ANSWER 5 OF 42 USPATFULL
 AN 2002:148570 USPATFULL
 TI Methods for designing exogenous regulatory molecules

IN Wolfe, Alan, Orinda, CA, UNITED STATES
 Urnov, Fyodor, Richmond, CA, UNITED STATES
 Guschin, Dmitry, Richmond, CA, UNITED STATES
 Collingwood, Trevor, San Pablo, CA, UNITED STATES
 Li, Xiao-Yong, Richmond, CA, UNITED STATES
 Johnstone, Brian, Benicia, CA, UNITED STATES
 PI US 2002076711 A1 20020620
 AI US 2001-844493 A1 20010427 (9)
 PRAI US 2000-200590P 20000428 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 5246
 INCL INCLM: 435/006.000
 NCL INCLS: 435/091.200; 702/020.000
 NCLM: 435/006.000
 NCLS: 435/091.200; 702/020.000
 IC [7]
 ICM: C120001-68
 ICS: G06F019-00; G01N033-48; G01N033-50; C12P019-34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L9 ANSWER 6 OF 42 USPATFULL
 AN 2002:133856 USPATFULL
 TI Tolerance and chronic hepatitis C virus
 IN Palard, Xavier, San Francisco, CA, UNITED STATES
 PI US 2002068714 A1 20020606
 AI US 2001-894845 A1 20010627 (9)
 PRAI US 2000-214583P 20000627 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1002
 INCL INCLM: 514/044.000
 NCL INCLS: 424/093.210; 800/014.000
 NCLM: 514/044.000
 NCLS: 424/093.210; 800/014.000
 IC [7]
 ICM: A01K067-027
 ICS: A61K048-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L9 ANSWER 7 OF 42 USPATFULL
 AN 2002:99410 USPATFULL
 TI Methods and compositions for the treatment and/or diagnosis of
 IN neurological diseases and disorders
 Solomon, Beki, Herzlia Pituach, ISRAEL
 PI US 2002052311 A1 20020502
 AI US 2001-808037 A1 20010315 (9)
 RLI Continuation-in-part of Ser. No. US 2000-629971, filed on 31 Jul 2000,
 PENDING Continuation-in-part of Ser. No. US 1999-473653, filed on 29 Dec
 1999, PENDING
 PRAI US 1999-152417P 19990903 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4074
 INCL INCLM: 514/002.000
 NCL INCLS: 424/093.210
 NCLM: 514/002.000
 NCLS: 424/093.210
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 42 USPATFULTL
 AN 2002:54662 USPATFULTL
 TI Use of trans-activation and cis-activation to modulate the persistence
 IN of expression of a transgene
 Brough, Douglas E., Galthersburg, MD, UNITED STATES
 PA Kovesdi, Imre, Rockville, MD, UNITED STATES
 PI US 200201823 AI 20020314
 AI US 2001-873486 AI 20010604 (9)
 RLI Continuation of Ser. No. WO 1999-US28637, filed on 3 Dec 1999, UNKNOWN
 Continuation-in-part of Ser. No. US 1998-205014, filed on 4 Dec 1998,
 GRANTED, Pat. No. US 6225113
 DT Utility
 FS APPLICATION
 LN.CNT 1159
 INCL INCLM: 435/320.100
 NCL INCLS: 514/044.000
 NCLM: 435/320.100
 NCLS: 514/044.000
 IC (7)
 ICM: A61K048-00
 ICS: C12N015-86
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 42 USPATFULTL
 AN 2002:48003 USPATFULTL
 TI Transgene expression systems
 IN Kaplan, Johanne, Sherborn, MA, UNITED STATES
 Armentano, Donna, Belmont, MA, UNITED STATES
 Gregory, Richard J., Westford, MA, UNITED STATES
 PI US 2002028194 AI 20020307
 AI US 2001-924925 AI 20010808 (9)
 RLI Continuation of Ser. No. US 1999-416673, filed on 12 Oct 1999, PENDING
 Continuation of Ser. No. WO 1998-US7839, filed on 14 Apr 1998, UNKNOWN
 Continuation of Ser. No. US 1997-839679, filed on 14 Apr 1997, GRANTED,
 Pat. No. US 6100086
 DT Utility
 FS APPLICATION
 LN.CNT 1489
 INCL INCLM: 424/093.210
 NCL INCLS: 435/456.000; 435/320.100
 NCLM: 424/093.210
 NCLS: 435/456.000; 435/320.100
 IC (7)
 ICM: A61K048-00
 ICS: C12N015-861
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 42 USPATFULTL
 AN 2002:37318 USPATFULTL
 TI Therapeutic DNA vaccination
 IN Lisiewicz, Juliana, Bethesda, MD, UNITED STATES
 Lori, Franco, Bethesda, MD, UNITED STATES
 PI US 2002022034 AI 20020221
 AI US 2001-863806 AI 20010523 (9)
 RLI Continuation-in-part of Ser. No. US 1998-153198, filed on 15 Sep 1998,
 PENDING
 PRAI US 1997-58933P 19970915 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2171
 INCL INCLM: 424/208.100
 NCL INCLS: 514/023.000; 514/044.000
 NCLM: 424/208.100

IC NCLS: 514/023.000; 514/044.000
 (7)
 ICM: A61K039-21
 ICS: A61K031-70; A61K048-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 42 USPATFULTL
 AN 2002:32230 USPATFULTL
 TI Chimeric adenoviral vectors
 IN Lusky, Monika, Freiburg, GERMANY, FEDERAL REPUBLIC OF
 Winter, Arend Jan, Strasbourg, FRANCE
 PI US 2002019051 AI 20020214
 AI US 2001-867475 AI 20010531 (9)
 RLI Continuation-in-part of Ser. No. US 2000-463486, filed on 27 Jan 2000,
 PENDING
 PRAI FR 1998-6654 19980527
 WO 1999-FR1238 19990527
 DT Utility
 FS APPLICATION
 LN.CNT 2525
 INCL INCLM: 435/457.000
 NCL INCLS: 435/235.100
 NCLM: 435/457.000
 NCLS: 435/235.100
 IC (7)
 ICM: C12N015-861
 ICS: C12N007-01
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 42 USPATFULTL
 AN 2002:31965 USPATFULTL
 TI Methods for producing polynucleotide libraries in vaccinia virus
 IN Zanderer, Maurice, Pittsford, NY, UNITED STATES
 PA University of Rochester (U.S. corporation)
 PI US 2002018785 AI 20020214
 AI US 2001-822250 AI 20010402 (9)
 RLI Division of Ser. No. US 1997-935377, filed on 22 Sep 1997, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 3321
 INCL INCLM: 424/232.100
 NCL INCLS: 435/235.100; 435/456.000
 NCLM: 424/232.100
 NCLS: 435/235.100; 435/456.000
 IC (7)
 ICM: A61K039-285
 ICS: C12N015-863; C12N007-01
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 42 USPATFULTL
 AN 2002:27111 USPATFULTL
 TI Diagnostics and therapeutics for macular degeneration-related disorders
 IN Hageman, Gregory S., Coralville, IA, UNITED STATES
 Mullins, Robert F., Coralville, IA, UNITED STATES
 PI US 2002015957 AI 20020207
 AI US 2001-845745 AI 20010430 (9)
 RLI US 2000-200698P 20000429 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3111
 INCL INCLM: 435/006.000
 NCL INCLS: 351/200.000
 NCLM: 435/006.000
 NCLS: 351/200.000

IC [7]
 ICM: C120001-68
 ICS: A61B003-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 42 USPTAFULL
 AN 2002:69599 USPTAFULL
 TI Cellular immunogens comprising cognate proto-oncogenes
 IN Halpern, Michael S., West Newton, MA, United States
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,
 PI United States (U.S. corporation)
 AI US 6365151 B1 20020402
 RLI US 1998-167322 19981007 (9)
 now abandoned Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,
 now abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on
 13 Jan 1997
 PRAI US 1996-10262P 19960119 (60)
 DT US 1996-10262P
 FS Utility
 INCL GRANTED
 LN.CNT 1838
 INCL INCLM: 424/093.210
 INCL INCLS: 424/093.200; 435/325.000; 435/320.100; 514/044.000
 NCL NCLM: 424/093.210
 NCL NCLS: 424/093.200; 435/320.100; 435/325.000; 514/044.000

IC [7]
 ICM: A61K035-00
 ICS: A61K048-00; C12N015-85; C12N015-63
 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 42 USPTAFULL
 AN 2002:57389 USPTAFULL
 TI Transgene expression systems
 IN Kaplan, Johanne, Sherborn, MA, United States
 PA Armentano, Donna, Belmont, MA, United States
 PI Gregory, Richard J., Westford, MA, United States
 US 6358507 B1 20020319
 AI US 1999-416673 19991012 (9)
 RLI Continuation of Ser. No. WO 1998-US7839, filed on 14 Apr 1998
 Continuation of Ser. No. US 1997-839679, filed on 14 Apr 1997, now
 patented, Pat. No. US 6100086
 DT Utility
 FS GRANTED
 INCL INCLM: 424/093.200
 INCL INCLS: 424/093.600; 435/320.100; 435/069.100; 435/455.000; 435/456.000;
 435/325.000; 435/366.000; 435/091.100; 435/091.400; 435/091.410;
 435/091.420; 435/371.000
 NCL NCLM: 424/093.200
 NCL NCLS: 424/093.600; 435/069.100; 435/091.100; 435/091.400; 435/091.410;
 435/091.420; 435/320.100; 435/325.000; 435/366.000; 435/371.000;
 435/455.000; 435/456.000

IC [7]
 ICM: A61K048-00
 ICS: C12N015-63; C12N015-861; C12N015-34
 435/320.1; 435/69.1; 435/455; 435/456; 435/325; 435/366; 435/91.1;
 435/91.4; 435/91.41; 435/91.42; 435/371; 424/93.2; 424/93.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 42 USPTAFULL
 AN 2002:34423 USPTAFULL
 TI Noninvasive genetic immunization, expression products therefrom and uses

IN thereof
 Tang, De-chu C., Birmingham, AL, United States
 Marks, Donald H., Rockaway, NJ, United States
 Curriel, David T., Birmingham, AL, United States
 Shi, Zhongkai, Birmingham, AL, United States
 van Kampen, Kent Rigby, Hoover, AL, United States
 The UAB Research Foundation, Birmingham, AL, United States (U.S.
 corporation)
 PA
 PI US 6348450 B1 20020219
 AI US 2000-563826 20000503 (9)
 RLI Continuation-in-part of Ser. No. US 2000-533149, filed on 23 Mar 2000
 Continuation-in-part of Ser. No. US 402527 Continuation-in-part of Ser.
 No. WO 1998-US16739, filed on 13 Aug 1998
 PRAI US 1999-122216P 19990503 (60)
 US 1998-75113P 19980211 (60)
 US 1997-55520P 19970813 (60)
 DT Utility
 FS GRANTED
 INCL INCLM: 514/044.000
 INCL INCLS: 424/093.210; 435/320.100; 435/375.000
 NCL NCLM: 514/044.000
 NCL NCLS: 424/093.210; 435/320.100; 435/375.000

IC [7]
 ICM: A61K048-00
 ICS: C12N015-63
 514/44; 424/93.21; 435/320.1; 435/375
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 42 USPTAFULL
 AN 2002:9856 USPTAFULL
 TI Gene construct encoding a heterologous produg-activating enzyme and a
 cell targeting moiety
 IN Emery, Stephen Charles, Macleesfield, UNITED KINGDOM
 PA Blakey, David Charles, Macleesfield, UNITED KINGDOM
 PI Zeneca Limited, London, UNITED KINGDOM (non-U.S. corporation)
 US 6339070 B1 20020115
 AI WO 9851787 19981119
 WO 1999-423439 19991109 (9)
 WO 1998-CB1294 19980505
 PRAI GB 1997-9421 19970510 PCT 371 date
 DT Utility
 FS GRANTED
 INCL INCLM: 514/044.000
 INCL INCLS: 424/093.200; 435/320.100; 435/325.000; 435/455.000; 435/458.000
 NCL NCLM: 514/044.000
 NCL NCLS: 424/093.200; 435/320.100; 435/325.000; 435/455.000; 435/458.000

IC [7]
 ICM: A61P048-00
 ICS: C12N015-00; C12N015-63; C12N015-88
 514/44; 536/23.1; 536/24.1; 435/320.1; 435/328; 435/456; 435/69.7;
 424/93.21; 424/134.1; 424/178.1; 424/94.1; 424/277.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 42 USPTAFULL
 AN 2001:229422 USPTAFULL
 TI HIGH EFFICIENCY GENETIC MODIFICATION METHODS
 IN KLAUGHERIN-TAYLOR, ELIZABETH, SAN CLEMENTE, CA, United States
 KLAUGHER, MARK, ENCINITAS, CA, United States
 LUNDAK, CHERYL, SAN DIEGO, CA, United States
 KILLION, CATHERINE, LONG BEACH, CA, United States
 PI US 2001051374 A1 20011213

AI US 1999-454820 A1 19991203 (9)
 RLI Continuation of Ser. No. US 1998-132541, filed on 11 Aug 1998, GRANTED.
 PRAI Pat. No. US 6114113
 DT US 1997-55453P 19970811 (60)
 FS Utility
 IN APPLICATION
 LN.CNT 3013
 INCL INCLM: 435/455.000
 NCL INCLS: 435/456.000; 435/320.100; 435/372.300
 NCLM: 435/455.000
 NCLS: 435/456.000; 435/320.100; 435/372.300
 IC [7]
 ICM: C120001-68
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 19 OF 42 USPATFULT.
 AN 2001:235126 USPATFULT.
 TI Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
 IN Levy, Robert J., Merion Station, PA, United States
 PA Crombleholme, Timothy, Haverford, PA, United States
 Vyahare, Narendra, Etal, NJ, United States
 The Children's Hospital of Philadelphia, Philadelphia, PA, United States
 (U.S. corporation) B1 20011225
 PI US 633194
 AI US 2000-487854 200000119 (9)
 PRAI US 1999-116538P 19990119 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3154
 INCL INCLM: 435/450.000
 NCL INCLS: 435/006.000; 424/001.250; 424/001.330; 424/001.530; 424/001.530; 424/497.000;
 NCLM: 435/003.000; 536/023.100
 NCLS: 424/001.250; 424/001.330; 424/001.530; 424/497.000; 435/006.000;
 IC [7]
 ICM: C12N015-63
 EXP 514/44; 435/6; 435/69.1; 435/91.1; 435/455; 435/458; 536/23.1; 536/24.5;
 536/3; 424/1.25; 424/1.33; 424/1.53; 424/497
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 20 OF 42 USPATFULT.
 AN 2001:226239 USPATFULT.
 TI Deleted adenovirus vectors and methods of making and administering the same
 IN Amalfitano, Andrea, Durham, NC, United States
 PA Chen, Yuan Tsong, Chapel Hill, NC, United States
 Hu, Hui-min, Memphis, TN, United States
 Duke University, Durham, NC, United States (U.S. corporation)
 PI US 6328958 B1 20011211
 AI US 1999-384749 19990827 (9)
 PRAI US 1998-145742P 19980828 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3884
 INCL INCLM: 424/093.200
 NCL INCLS: 435/091.400; 435/320.100; 435/455.000; 514/044.000
 NCLM: 424/093.200
 NCLS: 435/091.400; 435/320.100; 435/455.000; 514/044.000
 IC [7]

ICM: A61K048-00
 ICS: C12N015-88
 EXP 514/44; 435/320.1; 435/455; 435/69.1; 435/91.4; 536/23.4; 536/23.5;
 424/93.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 21 OF 42 USPATFULT.
 AN 2001:167936 USPATFULT.
 TI Hepatitis therapeutics
 IN Jolly, Douglas J., Leucadia, CA, United States
 Chang, Stephen M. W., Poway, CA, United States
 Lee, William T. L., Carlsbad, CA, United States
 Townsend, Kay, Encinitas, CA, United States
 O'Dea, Joanne, La Jolla, CA, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 6297048 B1 20011002
 AI US 1995-483511 19950607 (8)
 PRAI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,
 now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on
 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US
 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of
 Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned
 Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992,
 now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 3732
 INCL INCLM: 435/320.100
 NCL INCLS: 435/069.300
 NCLM: 435/320.100
 NCLS: 435/069.300
 IC [7]
 ICM: C12N015-63
 ICS: C12P021-02
 EXP 435/69.1; 435/69.3; 435/320.1; 424/228.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 22 OF 42 USPATFULT.
 AN 2001:152765 USPATFULT.
 TI Nucleic acid delivery vehicles
 IN O'Riordan, Catherine R., Boston, MA, United States
 Madsworth, Samuel C., Shrewsbury, MA, United States
 Genzyme Corporation, Cambridge, MA, United States (U.S. corporation)
 PI US 6287857 B1 20010911
 AI US 1999-426680 19991025 (9)
 PRAI Continuation-in-part of Ser. No. WO 1999-US2680, filed on 8 Feb 1999
 US 1998-107471P 19981106 (60)
 US 1998-135092P 19981103 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2871
 INCL INCLM: 435/320.100
 NCL INCLS: 536/023.100; 536/024.200
 NCLM: 435/320.100
 NCLS: 536/023.100; 536/024.200
 IC [7]
 ICM: C12N015-63
 ICS: C07H021-04
 EXP 435/320.1; 530/350; 536/23.1; 536/24.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 23 OF 42 USPATFULT.
 AN 2001:116818 USPATFULT.
 TI Packaging systems for human recombinant adenovirus to be used in gene

therapy, Frits J., Leiderdorp, Netherlands
 IN Fallaux, Robert C., Leiden, Netherlands
 Boue, Abraham, Moerkapelle, Netherlands
 Valerio, Domenico, Leiden, Netherlands
 van der Eb, Alex J., Oegstgeest, Netherlands
 Schouten, Govert, Leiden, Netherlands
 PA Introgene B.V., Leiden, Netherlands (non-U.S. corporation)
 PI US 6265212 B1 20010724
 AI US 1999-356575 19990719 (9)
 RLI Continuation-in-part of Ser. No. US 1997-793170, filed on 25 Mar 1997,
 now patented, Pat. No. US 5994128
 PRAI EP 1995-201613 19950615
 EP 1995-201728 19950626
 DT Utility
 FS GRANTED
 LN CNT 2294
 INCL INCLM: 435/320.100
 INCLS: 435/325.000; 435/069.100; 435/320.100; 435/235.100; 424/093.210;
 536/023.100
 NCLM: 435/320.100
 NCLS: 424/093.210; 435/069.100; 435/235.100; 435/325.000; 536/023.100
 IC [7]
 ICM: C12N015-63
 ICS: C12N015-00; C12N015-09; C12N015-11
 EXF 435/325; 435/69.1; 435/320.1; 435/455; 435/235.1; 424/93.21; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 24 OF 42 USPTFUL
 AN 2001:82751 USPTFUL
 TI Induction of immune response to antigens expressed by recombinant
 IN adeno-associated virus
 Kurtzman, Gary J., Menlo Park, CA, United States
 Engelman, Edgar G., Atherton, CA, United States
 Podakoff, Greg M., Fullerton, CA, United States
 Brockstedt, Dirk G., Palo Alto, CA, United States
 PA Avigen, Inc., CA, United States (U.S. corporation)
 PI US 624426 B1 20010605
 AI US 1998-121162 19980723 (9)
 PRAI US 1997-53733P 19970725 (60)
 DT Utility
 FS Granted
 LN CNT 2301
 INCL INCLM: 514/044.000
 INCLS: 435/320.100; 435/325.000
 NCLM: 514/044.000
 NCLS: 435/320.100; 435/325.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-63; C12N015-85
 EXF 435/320.1; 435/325.514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 25 OF 42 USPTFUL
 AN 2001:40206 USPTFUL
 TI Inhibition of smooth muscle cell migration by heme oxygenase I
 IN Nabel, Gary J., Washington, DC, United States
 Nabel, Elizabeth G., Washington, DC, United States
 PA The Regents of the University of Michigan, Ann Arbor, MI, United States
 (U.S. corporation)
 PI US 6203991 B1 20010320
 AI US 1999-378528 19990820 (9)
 PRAI US 1998-97707P 19980821 (60)
 DT Utility

FS Granted
 LN CNT 1607
 INCL INCLM: 435/006.000
 INCLS: 435/320.100; 435/458.000; 514/044.000; 536/023.100
 NCLM: 435/006.000
 NCLS: 435/320.100; 435/458.000; 514/044.000; 536/023.100
 IC [7]
 ICM: C12C001-68
 ICS: C12N015-63; C12N015-88; A61K048-00; C07H021-04
 EXF 435/6; 435/320.1; 435/458.514/44; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 26 OF 42 USPTFUL
 AN 2000:14950 USPTFUL
 TI Circular DNA expression cassettes for in vivo gene transfer
 IN Crouzet, Joel, Sceaux, France
 Scherman, Daniel, Paris, France
 Cameron, Beatrice, Paris, France
 Wils, Pierre, Paris, France
 PA Darquet, Anne-Marie, Villet-sur-Seine, France
 Rhone-Poulenc Rorer S.A., Antony, France (non-U.S. corporation)
 PI US 6143530 20001107
 PWO 9626270 19960829
 WO 1996-FR274 19970819 (8)
 AI US 1997-894511 19960221
 US 1997-894511 19970819 PCT 371 date
 19970819 PCT 102(e) date
 PRAI FR 1995-2117 19950223
 DT Utility
 FS Granted
 LN CNT 1941
 INCL INCLM: 435/091.420
 INCLS: 435/091.100; 435/091.400; 435/320.100; 435/325.000; 435/252.300;
 435/252.330; 435/254.110; 435/455.000; 514/044.000
 NCLM: 435/091.420
 NCLS: 435/091.100; 435/091.400; 435/252.300; 435/252.330; 435/254.110;
 435/320.100; 435/325.000; 435/455.000; 514/044.000
 IC [7]
 ICM: C12N015-64
 ICS: C12N015-79; C12N015-70; C12N001-21; C12N005-10
 EXF 514/44; 435/320.1; 435/325.435/252.3; 435/252.33; 435/254.11; 435/91.1;
 435/91.4; 435/91.42; 435/455
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 27 OF 42 USPTFUL
 AN 2000:146160 USPTFUL
 TI Defective viral vaccine particles obtained in vivo or ex vivo
 IN Klatzmann, David, Paris, France
 Salzmann, Jean-Loup, Paris, France
 PA Universite Pierre et Marie Curie (Paris VI), Paris, France (non-U.S.
 corporation)
 PI US 6140114 20001031
 AI US 1998-166147 19981005 (9)
 DT Utility
 FS Granted
 LN CNT 755
 INCL INCLM: 435/320.100
 INCLS: 424/184.100; 424/187.100; 424/188.100; 424/204.100;
 435/147.000FOR; 435/157.000FOR; 435/180.000FOR; 435/182.000FOR;
 435/190.000FOR; 536/023.100; 536/023.720
 NCLM: 435/320.100
 NCLS: 424/184.100; 424/187.100; 424/188.100; 424/204.100; 536/023.100;
 536/023.720
 IC [7]

ICM: C12N015-00
 EXF 435/320.1; 435/FOR147; 435/FOR148; 435/FOR157; 435/FOR180; 435/FOR182;
 435/FOR190; 424/184.1; 424/185.1; 424/186.1; 424/187.1; 424/188.1;
 424/189.1; 424/192.1; 424/196.1; 424/199.1; 424/204.1; 424/228.1;
 935/22; 935/23; 935/32; 935/55; 935/57; 935/65; 536/23.1; 536/23.72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 42 USPTAFULL
 AN 2000:142359 USPTAFULL
 TI Prostate specific enhancer polynucleotides and methods of use thereof
 IN Henderson, Daniel R., Palo Alto, CA, United States
 PA Calydon, Inc., Sunnyvale, CA, United States (U.S. corporation)
 PI US 6136732
 US 1997-891581 20001024
 19970711 (8)
 RLI Continuation of Ser. No. US 1995-380916, filed on 30 Jan 1995, now
 patented Pat. No. US 5648478 which is a continuation-in-part of Ser.
 No. US 1994-18247, filed on 13 Jan 1994, now patented, Pat. No. US
 5830686
 DT Utility
 FS Granted
 LN.CNT 1773
 INCL INCLM: 514/044.000
 INCLS: 536/024.100; 435/320.100; 435/325.000; 435/455.000
 NCLM: 514/044.000
 NCLS: 435/320.100; 435/325.000; 435/455.000; 536/024.100
 IC [7]
 ICM: A61K048-00
 ICS: C07H021-04; C12N005-00; C12N015-00
 800/2; 514/44; 424/93.21; 435/325; 435/320.1; 435/172.3
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 42 USPTAFULL
 AN 2000:138079 USPTAFULL
 TI Methods and compositions for enhanced stability of non-adenoviral DNA
 IN Kay, Mark A., Seattle, WA, United States
 PA Lieber, Andre, Seattle, WA, United States
 PI US 6132969 20001017
 US 1997-972657 19971118 (8)
 RLI Continuation-in-part of Ser. No. US 1997-867012, filed on 2 Jun 1997,
 now abandoned
 PRAI US 1996-18928P 19960603 (60)
 DT Utility
 FS Granted
 LN.CNT 1601
 INCL INCLM: 435/069.100
 INCLS: 435/448.000; 435/455.000; 435/456.000; 435/320.100
 NCLM: 435/069.100
 NCLS: 435/320.100; 435/448.000; 435/455.000; 435/456.000
 IC [7]
 ICM: C12N015-00
 ICS: 435/172.3; 435/69.1; 435/320.1; 435/370; 435/458; 435/235.1; 514/44;
 536/23.1; 536/23.72; 536/29.1
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 42 USPTAFULL
 AN 2000:117494 USPTAFULL
 TI High efficiency genetic modification method
 IN McLaughlin-Taylor, Elizabeth, San Clemente, CA, United States
 PA Krueger, Mark, Encinitas, CA, United States
 PI Lundak, Cheryl, San Diego, CA, United States
 Killion, Catherine, Long Beach, CA, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 US 6114113 20000905

AI US 1998-132541 19980811 (9)
 PRAI US 1997-55453P 19970811 (60)
 DT Utility
 FS Granted
 LN.CNT 3069
 INCL INCLM: 435/005.000
 INCLS: 435/440.000; 435/455.000; 435/456.000; 435/372.300
 NCLM: 435/005.000
 NCLS: 435/372.300; 435/440.000; 435/455.000; 435/456.000
 IC [7]
 ICM: C12N001-68
 ICS: C12Q001-70; C12N015-86
 514/44; 435/320.1; 435/235.1; 435/325; 435/375; 435/440; 435/455;
 424/93.1; 424/93.2
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 31 OF 42 USPTAFULL
 AN 2000:113772 USPTAFULL
 TI Diminishing viral gene expression by promoter replacement
 IN Fang, Bingliang, Houston, TX, United States
 PA Roth, Jack A., Houston, TX, United States
 PI Board of Regents, The University of Texas System, Austin, TX, United
 States (U.S. corporation)
 US 6110744 20000829
 US 1997-968014 19971112 (8)
 PRAI US 1996-30675P 19961113 (60)
 DT Utility
 FS Granted
 LN.CNT 3104
 INCL INCLM: 435/456.000
 INCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;
 536/024.100
 NCLM: 435/456.000
 NCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;
 536/024.100
 IC [7]
 ICM: C12N015-64
 ICS: C12N015-34; C12N015-12
 435/69.1; 435/325; 435/320.1
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 42 USPTAFULL
 AN 2000:113519 USPTAFULL
 TI Liposomal delivery system for biologically active agents
 IN Thierry, Alain R., Strasbourg, France
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. government)
 PI US 6110490 20000829
 US 1996-522246 19960129 (8)
 WO 1995-US9867 19950804
 RLI Continuation-in-part of Ser. No. US 1994-286730, filed on 5 Aug 1994
 DT Utility
 FS Granted
 LN.CNT 1758
 INCL INCLM: 424/450.000
 INCLS: 424/400.000; 935/054.000
 NCLM: 424/450.000
 NCLS: 424/400.000
 IC [7]
 ICM: A61K009-127
 424/450; 935/54
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NCL	NCLM: 514/044.000	
NCLS: 424/450.000		
IC	ICM: A61K048-00	
	71	
EXF	514/44; 424/450	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L9	ANSWER 36 OF 42 USPATFULL	
AN	2000:54082 USPATFULL	
TI	Tissue-specific enhancer active in prostate	
IN	Henderson, Daniel R., Palo Alto, CA, United States	
PA	Caldon, Inc., Sunnyvale, CA, United States (U.S. corporation)	
PI	US 6057299	
ALI	US 1996-721690	
RLI	200000502	
	19960927 (8)	
	Continuation-in-part of Ser. No. US 1995-380916, filed on 30 Jan 1995,	
	now patented, Pat. No. US 5648478 which is a continuation-in-part of	
	Ser. No. US 1994-182247, filed on 13 Jan 1994, now patented, Pat. No. US	
	5830686 And a continuation-in-part of Ser. No. US 1996-669753, filed on	
	26 Jun 1996, now patented, Pat. No. US 5871726 which is a	
	continuation-in-part of Ser. No. US 1995-495034, filed on 27 Jun 1995,	
	now patented, Pat. No. US 5698443	
DT	Utility	
FS	Granted	
LN	CNT 2614	
INCL	INCLM: 514/044.000	
	INCLS: 536/022.100; 536/024.100; 435/069.100; 435/320.100; 435/325.000;	
NCL	435/455.000; 435/458.000; 424/093.210	
	NCLM: 514/044.000	
	NCLS: 424/093.210; 435/069.100; 435/320.100; 435/325.000; 435/455.000;	
IC	435/458.000; 536/023.100; 536/024.100	
	(7)	
ICM:	A61K048-00	
EXF	435/320.1; 435/172.3; 435/325; 514/2; 514/44; 424/93.21; 536/23.1;	
	536/24.1; 935/51; 935/61; 935/63; 935/455; 935/458; 935/69.1	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L9	ANSWER 37 OF 42 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.	
AN	2000416349 EMBASE	
TI	Adeno-associated virus production of soluble tumor necrosis factor	
IN	receptor neutralizes tumor necrosis factor, alpha, and reduces arthritis.	
AU	Zhang H.-G.; Xie J.; Yang P.; Wang Y.; Xu L.; Liu D.; Heu H.-C.; Zhou T.;	
CS	Edwards III C.K.; Mount J.D.	
	Dr. J.D. Mount, Div. of Clin. Immunol./Rheumatology, Department of	
	Medicine, University of Alabama, 701 South 19th Street, Birmingham, AL	
	35294, United States. john.mount@ccc.uab.edu	
SO	Human Gene Therapy, (20 Nov 2000) 11/17 (2431-2442).	
	Refs: 33	
	ISSN: 1043-0342 CODEN: HGTHE3	
CY	United States	
DT	Journal; Article	
FS	031 Arthritis and Rheumatism	
PA	037 Drug Literature Index	
LA	English	
SL	English	
L9	ANSWER 38 OF 42 USPATFULL	
AN	1998:138874 USPATFULL	
TI	Adeno-associated viral (AAV) liposomes and methods related thereto	
IN	Phillip, Ramli, Redwood City, CA, United States	
PA	Lebowski, Jane, Portola Valley, CA, United States	
	Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United	
	States (U.S. corporation)	
PI	US 5834441	
	19981110	
ALI	US 1994-305221	
	19940912 (8)	

RLI Continuation-in-part of Ser. No. US 1993-120605, filed on 13 Sep 1993,
now abandoned

DT Utility
FS Granted
LN.CNT 2039

INCL INCLM: 514/044.000
INCLS: 424/093.210; 424/450.000; 435/069.100; 435/172.300; 435/320.100;
435/325.000; 536/024.100; 935/022.000; 935/034.000; 935/056.000;
935/060.000; 935/062.000; 935/070.000

NCL NCLM: 514/044.000
NCLS: 424/093.210; 424/450.000; 435/069.100; 435/320.100; 435/325.000;
435/456.000; 536/024.100

IC [6]
ICM: A01N063-00

EXF ICS: A61K048-00; A61K009-127; C12N005-00
514/44; 514/2; 435/320.1; 435/172.3; 435/240.2; 435/69.1;
435/325; 424/93.1; 424/93.21; 424/450; 536/24.1; 935/22; 935/34; 935/56;
935/60; 935/62; 935/70

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 39 OF 42 USPATFULT.
AN 1998.134840 USPATFULT.
TI Tissue-specific enhancer active in prostate
IN Henderson, Daniel R., Palo Alto, CA, United States
PA Calydon, Menlo Park, CA, United States (U.S. corporation)
PI US 5830686 19981103
AI US 1994-182247 19940113 (8)
DT Utility
FS Granted
LN.CNT 1169

INCL INCLM: 435/069.100
INCLS: 435/240.200; 435/320.100; 536/024.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/455.000; 536/024.100

IC [6]
ICM: C12N015-00
ICS: C12N015-85; C12N015-63; C07H021-04
514/44; 536/24.1; 435/320.1

EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 42 USPATFULT.
AN 97.91712 USPATFULT.
TI Transgenic arthritic mice expressing a T-cell receptor transgene
IN Benoist, Christophe O., Strasbourg, France
PA Mathis, Diane U., Strasbourg, France
Kouskoff, Valerie, Denver, CO, United States
Institut National de la Sante et de la Recherche Medicale, Paris, France
(non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris, France (non-U.S.
government)
Universite Louis Pasteur, Strasbourg 1, Paris, France (non-U.S.
corporation)
E.R. Squibb & Sons, Inc., Princeton, NJ, United States (U.S.
corporation)
PI US 5675060 19971007
AI US 1994-246242 19940519 (8)
DT Utility
FS Granted
LN.CNT 2377

INCL INCLM: 800/002.000
INCLS: 424/009.200
NCL NCLM: 800/003.000
NCLS: 424/009.200; 800/009.000

IC [6]

EXF ICM: C12N005-00
ICS: C12P015-00; A61K049-00
800/2; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 41 OF 42 USPATFULT
AN 97.6611 USPATFULT
TI Methods and compositions for gene therapy for the treatment of defects
in lipoprotein metabolism
IN Wilson, James M., Gladwyne, PA, United States
Kozarsky, Karen, Philadelphia, PA, United States
Strauss, III, Jerome, Wyndmoor, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)
PI US 5652224 19970729
AI US 1995-393734 19950224 (8)
DT Utility
FS Granted
LN.CNT 2079

INCL INCLM: 514/044.000
INCLS: 424/093.210; 435/172.300; 435/320.100; 435/325.000; 435/354.000;
435/366.000; 435/370.000
NCL NCLM: 514/044.000
NCLS: 424/093.210; 435/320.100; 435/325.000; 435/354.000; 435/366.000;
435/369.000; 435/370.000; 435/456.000

IC [6]
ICM: A61K048-00
ICS: C12N015-00
424/93.21; 435/320.1; 435/240.2; 435/172.3; 435/240.1; 514/44; 514/2;
536/22.1; 530/350

EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 42 USPATFULT
AN 97.61806 USPATFULT
TI Tissue-specific enhancer active in prostate
IN Henderson, Daniel R., 769 Garland Dr., Palo Alto, CA, United States
PI US 5648478 19970715
AI US 1995-380916 19950130 (8)
RLI Continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994
DT Utility
FS Granted
LN.CNT 1499

INCL INCLM: 536/241.000
INCLS: 435/320.100
NCL NCLM: 536/024.100
NCLS: 435/320.100

IC [6]
ICM: C07H021-04
ICS: C12N015-63
514/44; 536/24.1; 435/320.1

EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULT, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002
538 S IMMUNOGEN? (S) TRANSENER?
L1 52 S L1 AND ALLOGEN?
L2 27 S L2 AND PROMOT?
L3 11 S L3 NOT PY>1998
L4

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9725860	A1	19970724	NO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KR, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TW, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW	AA	19970724	CA 1997-2241952	19970113
CA 2241952	AI	19970811	AU 1997-16992	19970113
AU 9716992	B2	20000233	EP 1997-902934	19970113
AU 713356	AI	19990623	EP 1997-902934	19970113
EP 923284	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	T2	20010213	JP 1997-526124
JP 2001501909	B1	20020402	US 1998-167322	19981007
US 6365151	P	19960119		
PRAI US 1996-10262P	W	19970113		
US 1997-US582	B2	19980702		
US 1998-101226				
L11 ANSWER 6 OF 30 USPTAFULL				
AN 1993:493480 CAPLUS				
DN 119:93480				
TI Superantigen-induced peripheral tolerance inhibits T cell responses to immunogenic peptides in TCR (beta-chain) transgenic mice				
AU Perkins, David L.; Wang, Yunsheng; Ho, Sai Sun; Wiens, Garth R.; Seidman, J. G.; Rimm, Ilona J.				
CS Lab. Immunogenet. Transplant., Brigham Women's Hosp., Boston, MA, 02115, USA				
SO J. Immunol. (1993), 150(10), 4284-91				
DT CODEN: JOIMAJ; ISSN: 0022-1767				
LA Journal				
English				
L11 ANSWER 7 OF 30 USPTAFULL				
AN 2002:16378 USPTAFULL				
TI Minimal adenovirus mediated recombinant vaccine				
Fang, Xiangming; San Diego, CA, UNITED STATES				
Galichan, Scott; San Diego, CA, UNITED STATES				
Zhang, Wei-Wei; San Diego, CA, UNITED STATES				
Wong, Staal, Flossie; San Diego, CA, UNITED STATES				
Sauter, Sybille; Del Mar, CA, UNITED STATES				
PI US 2002088014 AI 20020704				
US 2001-974206 AI 20011010 (9)				
Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997, PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, PENDING				
PRAI US 2000-239224P 20001010 (60)				
US 2000-241625P 20001019 (60)				
DT Utility				
FS APPLICATION				
LN.CNT 4062				
INCL INCLM: 800/008.000				
INCL INCLS: 435/320.100; 435/456.000; 435/235.100				
NCL NCLM: 800/008.000				
NCLS: 435/320.100; 435/456.000; 435/235.100				
IC [7]				
ICM: A01K067-00				
ICS: C12N015-867; C12N015-861; C12N007-00; C12N007-01				

L11 ANSWER 8 OF 30 USPTAFULL

AN 2002:144239 USPTAFULL

TI Tumor antigens and CTL clones isolated by a novel procedure

IN Luiten, Rosalie; Brussels, BELGIUM

Dufour, Marie-Therese; Brussels, BELGIUM

Demotte, Nathalie; Brussels, BELGIUM

van der Bruggen, Pierre; Brussels, BELGIUM

Cornelius, Guy; Brussels, BELGIUM

Serocbant, Vincent; Brussels, BELGIUM

Lurquin, Christophe; Brussels, BELGIUM

Boon-Fallier, Thierry; Brussels, BELGIUM

Ludwig Institute for Cancer Research, New York, NY, United States (U.S. corporation)

PA Universite Catholique de Louvain, Louvain-la-Neuve, BELGIUM (non-U.S. corporation)

PI US 6407063 B1 20020618

US 1998-165863 19981002 (9)

AI Utility

DT GRANTED

FS 1456

LN.CNT 1456

INCL INCLM: 514/013.000

INCLS: 530/326.000; 530/328.000; 514/015.000

NCL NCLM: 514/013.000

NCLS: 530/326.000; 530/328.000; 514/015.000

IC [7]

ICM: A61K038-08

ICS: A61K038-10; C07K007-06; C07K007-08

EXP 514/15; 514/13; 530/328; 530/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 30 USPTAFULL

AN 2002:133493 USPTAFULL

TI 98P703: homeodomain protein highly expressed in various cancers

IN Challita-Eid, Pia M.; Encino, CA, UNITED STATES

Hubert, Rene S.; Los Angeles, CA, UNITED STATES

Faris, Mary; Los Angeles, CA, UNITED STATES

Afar, Daniel E.H.; Brisbane, CA, UNITED STATES

Levin, Elana; Los Angeles, CA, UNITED STATES

Mitchell, Steve; Beverly Hills, Santa Monica, CA, UNITED STATES

Jakobovits, Aya; Beverly Hills, Santa Monica, CA, UNITED STATES

PI US 2002068345 AI 20020606

US 2001-866359 AI 20010524 (9)

PRAI US 2000-207138P 20000524 (60)

PI Jakovovics, Aya, Beverly Hills, CA, UNITED STATES
 AI US 2002055478 AI 20020509
 PRAI US 2001-834765 AI 20010412 (9)
 DT US 2000-196647P 20000412 (60)
 FS APPLICATION
 LN CNT 5003
 INCL INCLM: 514/044.000
 NCL INCLM: 435/006.000; 435/007.230
 NCLM: 514/044.000
 NCLM: 435/006.000; 435/007.230
 IC [7]
 ICM: A61K048-00
 ICS: C120001-68; C01N033-574
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L11 ANSWER 11 OF 30 USPATFULT
 AN 2002:84909 USPATFULT
 TI Methods and compositions for co-stimulation of immunological responses to peptide antigens
 IN Khleif, Samir, Silver Spring, MD, UNITED STATES
 PI Berzofsky, Jay, Bethesda, MD, UNITED STATES
 AI US 2002044948 AI 20020418
 PRAI US 2001-810310 AI 20010314 (9)
 DT US 2000-189396P 20000315 (60)
 FS APPLICATION
 LN CNT 3104
 INCL INCLM: 424/234.100
 NCL INCLM: 424/184.100; 530/350.000
 NCLM: 424/234.100
 NCLM: 424/184.100; 530/350.000
 IC [7]
 ICM: A61K039-00
 ICS: A61K039-18; A61K039-02; C07K001-00; C07K014-00; C07K017-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L11 ANSWER 12 OF 30 USPATFULT
 AN 2002:78215 USPATFULT
 TI Cell fusions and methods of making and using the same
 IN Nicolette, Charles, Framingham, MA, UNITED STATES
 PI Roberts, Bruce L., Southboro, MA, UNITED STATES
 RLI Gong, Jianlin, Brookline, MA, UNITED STATES
 PI Kufe, Donald, Wellesley, MA, UNITED STATES
 AI US 2002041868 AI 20020411
 RLI US 2001-782492 AI 20010212 (9)
 Continuation-in-part of Ser. No. US 2000-618917, filed on 18 Jul 2000,
 PENDING Continuation of Ser. No. US 1998-60603, filed on 15 Apr 1998,
 ABANDONED Continuation of Ser. No. US 2000-642701, filed on 12 Aug 2000,
 UNKNOWN A 371 of International Ser. No. WO 1999-US1464, filed on 25 Jan
 1999, UNKNOWN
 PRAI US 1997-43609P 19970415 (60)
 US 2000-181822P 20000211 (60)
 US 2000-184687P 20000224 (60)
 US 1998-80041P 19980331 (60)
 US 1998-88357P 19980126 (60)
 DT Utility
 FS APPLICATION
 LN CNT 3318
 INCL INCLM: 424/093.210
 NCL INCLM: 424/277.100; 435/449.000
 NCLM: 424/093.210
 NCLM: 424/277.100; 435/449.000
 IC [7]

ICM: A61K048-00
 ICS: A61K039-00; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L11 ANSWER 13 OF 30 USPATFULT
 AN 2002:69599 USPATFULT
 TI Cellular immunogens comprising cognate
 IN Halpern, Michael S, West Newton, MA, United States
 PA England, James M, Media, PA, United States
 PA Philadelphia Health and Educational Corporation, Philadelphia, PA,
 United States (U.S. corporation)
 PI US 6365151 BI 20020402
 AI US 1998-167322 BI 19981007 (9)
 RLI Continuation-in-part of Ser. No. US 1998-101226, filed on 2 Jul 1998,
 now abandoned Continuation-in-part of Ser. No. WO 1997-US582, filed on
 13 Jan 1997
 PRAI US 1996-10262P 19960119 (60)
 DT Utility
 FS GRANTED
 LN CNT 1838
 INCL INCLM: 424/093.210
 NCL INCLM: 424/093.200; 435/325.000; 435/320.100; 514/044.000
 NCLM: 424/093.210
 NCLM: 424/093.200; 435/320.100; 435/325.000; 514/044.000
 IC [7]
 ICM: A61K035-00
 ICS: A61K048-00; C12N015-85; C12N015-63
 EXF 435/325; 435/320.1; 424/93.2; 424/93.21; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L11 ANSWER 14 OF 30 USPATFULT
 AN 2002:54318 USPATFULT
 TI Porcine neural cells and their use in treatment of neurological deficits
 IN Fraser, Thomas, Newton, MA, UNITED STATES
 PA Dinmore, Jonathan, Brookline, MA, UNITED STATES
 PI Diacrin, Inc. (U.S. corporation)
 AI US 2002031497 AI 20020314
 AI US 2001-843270 AI 20010426 (9)
 RLI Division of Ser. No. US 1995-424855, filed on 19 Apr 1995, GRANTED, Pat.
 No. US 6277372 Continuation-in-part of Ser. No. US 1994-336856, filed on
 8 Nov 1994, ABANDONED
 DT Utility
 FS APPLICATION
 LN CNT 3959
 INCL INCLM: 424/093.700
 NCL INCLM: 435/325.000
 NCLM: 424/093.700
 NCLM: 435/325.000
 IC [7]
 ICM: A61K045-00
 ICS: C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L11 ANSWER 15 OF 30 USPATFULT
 AN 2002:24275 USPATFULT
 TI Herpes virus vectors and their uses
 IN Bourneil, Michael Edward Griffith, Cambridge, UNITED KINGDOM
 PI Brenner, Malcolm Keith, Memphis, TN, United States
 PA Dilloo, Dagmar, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
 Inglis, Stephen Charles, Cambridge, UNITED KINGDOM
 PA Cantab pharmaceutical Research Limited, Cambridge, UNITED KINGDOM
 (non-U.S. corporation)

St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)

PI US 6344445 B1 20020205
 AI US 1996-734054 19961018 (8)
 PRAI US 1995-5649P 19951019 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1789
 INCL INCLM: 514/044.000
 INCLS: 435/456.000
 NCLM: 514/044.000
 NCLS: 435/456.000
 IC [7]
 ICM: A61K031-70
 ICS: C12N015-86
 EXF 514/44; 435/456; 435/472
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 30 USPATFULT.
 AN 2002:19216 USPATFULT.
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6
 IN Marchetti, Antonio, Viareggio, ITALY
 Butitta, Piamma, Viareggio, ITALY
 Smith, Gilbert H., Falls Church, VA, United States
 Callahan, Robert, Alexandria, VA, United States
 PA The United States of America as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. corporation)
 PI US 6342392 B1 20020129
 AI US 1999-378842 19990823 (9)
 RLI Division of Ser. No. US 875847 Continuation-in-part of Ser. No. US
 1995-385998, filed on 9 Feb 1995, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 2076
 INCL INCLM: 436/063.000
 INCLS: 436/086.000; 435/006.000
 NCLM: 436/063.000
 NCLS: 435/006.000; 436/086.000
 IC [7]
 ICM: G01N033-48
 ICS: G01N033-00; C12N001-68
 EXF 514/12; 436/63; 436/86; 435/6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 30 USPATFULT.
 AN 2002:16585 USPATFULT.
 TI Porcine neural cells and their use in treatment of neurological deficits
 IN due to neurodegenerative diseases
 Isaacson, Ole, Cambridge, MA, UNITED STATES
 Dinamore, Jonathan, Brookline, MA, UNITED STATES
 PA Diacrin, Inc. (U.S. corporation)
 PI US 2002009461 A1 20020124
 AI US 2001-847881 A1 20010502 (9)
 RLI Division of Ser. No. US 1995-554779, filed on 7 Nov 1995, GRANTED. Pat.
 No. US 6258353 Continuation-in-part of Ser. No. US 1995-424851, filed on
 19 Apr 1995, GRANTED. Pat. No. US 6294383 Continuation-in-part of Ser.
 No. US 1994-33856, filed on 8 Nov 1994, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 5037
 INCL INCLM: 424/193.100
 INCLS: 424/093.700; 435/325.000
 NCLM: 424/193.100
 NCLS: 424/093.700; 435/325.000

IC [7]
 ICM: A61K039-385
 ICS: C12N005-06; A61K045-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 30 USPATFULT.
 AN 2002:13790 USPATFULT.
 TI Superantigen based methods and compositions for treatment of diseases
 IN Terman, David Stephen, 3183 Palmero Way, Pebble Beach, CA, United States
 93953
 PI US 6340461 B1 20020122
 AI US 1997-992877 19970127 (8)
 PRAI US 1996-33172P 19961217 (60)
 DT US 1997-44074P 19970417 (60)
 FS Utility
 FS GRANTED
 LN.CNT 5893
 INCL INCLM: 424/193.100
 INCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700
 NCLM: 424/193.100
 NCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700
 IC [7]
 ICM: A61K039-385
 ICS: A61K039-00; A61K039-39; A61K045-00; C12N015-09; C12N015-12;
 C12N015-62; C12N015-63
 EXF 424/277.1; 424/193.1; 424/194.1; 424/192.1; 424/278.1; 424/280.1;
 424/282.1; 435/68.1; 435/69.7; 435/69.3; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 30 USPATFULT.
 AN 2001:205415 USPATFULT.
 TI ADENOVIRUS-BASED METHODS, AND CELLS, USEFUL FOR THE EXPRESSION OF
 IN NUCLEIC ACID SEQUENCES
 GRAHAM, FRANK L., HAMILTON, Canada
 ANTON, MARTINA, VATERSTEIN, Germany, Federal Republic of
 RUDNICKI, MICHAEL A., DUNDAS, Canada
 PI US 2001041173 A1 20011115
 AI US 1999-251955 A1 19990217 (9)
 RLI Continuation-in-part of Ser. No. US 1995-473168, filed on 7 Jun 1995,
 UNKNOWN
 DT Utility
 FS APPLICATION
 LN.CNT 1227
 INCL INCLM: 424/093.210
 INCLS: 536/023.100; 435/456.000; 435/465.000; 435/320.100; 514/044.000
 NCLM: 424/093.210
 NCLS: 536/023.100; 435/456.000; 435/465.000; 435/320.100; 514/044.000
 IC [7]
 ICM: A61K048-00
 ICS: C07H021-04; C12N015-87
 EXF 514/12; 436/63; 436/86; 435/6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 30 USPATFULT.
 AN 2001:167936 USPATFULT.
 TI Hepatitis therapeutics
 IN Jolly, Douglas J., Leucadia, CA, United States
 Chang, Stephen M. W., Poway, CA, United States
 Lee, William T. L., Carlsbad, CA, United States
 Townsend, Kay, Encinitas, CA, United States
 O'Dea, Joanne, La Jolla, CA, United States
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 6297048 B1 20011002

AI US 1995-483511 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995, now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992, now abandoned

DT Utility
 FS GRANTED
 LN CNT 3732
 INCL INCLM: 435/320.100
 NCL INCLS: 435/069.300
 NCL NCLS: 435/069.300
 IC [7]
 ICM: C12N015-63
 ICS: C12P021-02
 EXF 435/69.1; 435/69.3; 435/320.1; 424/228.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 30 USPTAFULL
 AN 2001:163053 USPTAFULL
 TI Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 IN Isaacson, Ole, Cambridge, MA, United States
 PA The McLean Hospital Corporation, Belmont, MA, United States (U.S. corporation)
 PI Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
 AI US 6294383 B1 20010925
 US 1995-424851 19950419 (8)
 RLI Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned

DT Utility
 FS GRANTED
 LN CNT 4123
 INCL INCLM: 435/379.000
 NCL INCLS: 435/325.000
 NCL NCLS: 435/379.000
 IC [7]
 ICM: C12N005-00
 ICS: C12N005-02
 EXF 435/240.1; 435/240.2; 435/325.435/379
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 30 USPTAFULL
 AN 2001:136181 USPTAFULL
 TI Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 IN Fraser, Thomas, Newton, MA, United States
 PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
 PI US 6277372 B1 20010821
 US 1995-424855 19950419 (8)
 RLI Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned

DT Utility
 FS GRANTED
 LN CNT 4112
 INCL INCLM: 424/093.700
 NCL INCLS: 424/093.100; 435/325.000
 NCL NCLM: 424/093.700

IC NCLS: 424/093.100; 435/325.000
 [7]
 ICM: A01N063-00
 ICS: C12N005-02; C12N005-06
 EXF 435/325; 424/93.1; 424/93.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 30 USPTAFULL
 AN 2001:107439 USPTAFULL
 TI Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
 IN Isaacson, Ole, Cambridge, MA, United States
 PA Diacrin, Inc., Charlestown, MA, United States (U.S. corporation)
 PI US 6258153 B1 20010710
 US 1995-554779 19951107 (8)
 RLI Continuation-in-part of Ser. No. US 1995-424851, filed on 19 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994, now abandoned

DT Utility
 FS GRANTED
 LN CNT 5157
 INCL INCLM: 424/093.100
 NCL INCLS: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000; 435/368.000
 NCL NCLM: 424/093.100
 NCL NCLS: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000; 435/368.000
 IC [7]
 ICM: A01N003-00
 ICS: C12N015-85; C12N015-86; A61K039-395
 EXF 424/93.7; 424/93.1; 424/130.1; 424/143.1; 424/809; 435/325; 435/368
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 30 USPTAFULL
 AN 2001:102615 USPTAFULL
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6
 IN Marchetti, Antonio, Viareggio, Italy
 PA Buttitella, Fiama, Viareggio, Italy
 PA Smith, Gilbert H., Falls Church, VA, United States
 PA Callahan, Robert, Alexandria, VA, United States
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 6255105 B1 20010703
 US 9624672 19970815
 AI US 1997-875847 19970925 (8)
 WO 1996-US1864 19960209
 PCT 371 date
 19970925 PCT 102(e) date
 19970925

RLI Continuation-in-part of Ser. No. US 1995-385998, filed on 9 Feb 1995, now abandoned

DT Utility
 FS GRANTED
 LN CNT 1789
 INCL INCLM: 435/325.000
 NCL INCLS: 435/325.300; 435/320.100; 435/069.100
 NCL NCLM: 435/325.000
 NCL NCLS: 435/069.100; 435/252.300; 435/320.100
 IC [7]
 ICM: C12N005-00
 ICS: C12N015-00; C12N001-20; C12P021-06
 EXF 435/69.1; 435/320.1; 435/325; 435/252.3; 435/366; 435/371; 435/252.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 30 USPATFUL.
 AN 2001:40268 USPATFUL.
 TI Porcine cortical cells and their use in treatment of neurological
 IN deficits due to neurodegenerative diseases
 PA Dinmore, Jonathan, Brookline, MA, United States
 PI Diarrin, Inc., Charlestown, MA, United States (U.S. corporation)
 AI US 6204053 B1 20010320
 RLI US 1995-424856 19950419 (8)
 DT Continuation-in-part of Ser. No. US 1994-336856, filed on 8 Nov 1994,
 now abandoned
 FS Utility
 INCL Granted
 LN.CNT 3891
 INCLM: 435/325.000
 INCLS: 424/093.700; 435/374.000
 NCLM: 435/325.000
 NCLS: 424/093.700; 435/374.000
 IC [7]
 ICM: C12N005-00
 EXP 435/240.2; 435/325; 435/374; 424/93.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 30 USPATFUL.
 AN 2000:146162 USPATFUL.
 TI Isolated and modified porcine cerebral cortical cells
 IN Dinmore, Jonathan, Brookline, MA, United States
 PA Diarrin, Inc., Charlestown, MA, United States (U.S. corporation)
 PI US 6140116 20001031
 AI US 1995-551820 19951107 (8)
 RLI Continuation-in-part of Ser. No. US 1995-424856, filed on 19 Apr 1995
 which is a continuation-in-part of Ser. No. US 1995-336856, filed on 8
 Nov 1995, now abandoned
 DT Utility
 FS Granted
 INCL 5001
 LN.CNT 5001
 INCLM: 435/325.000
 INCLS: 435/374.000; 424/093.700
 NCLM: 435/325.000
 NCLS: 424/093.700; 435/374.000
 IC [7]
 ICM: C12N005-00
 EXP 435/325; 435/374; 435/93.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 30 USPATFUL.
 AN 2000:124543 USPATFUL.
 TI Compositions and methods for enhanced tumor cell immunity in vivo
 IN Fakhrat, Habib, La Jolla, CA, United States
 PA Dorigo, Oliver, San Diego, CA, United States
 PI Sobol, Robert E., Rancho Santa Fe, CA, United States
 RLI Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S.
 corporation)
 AI US 6120763 20000919
 DT US 1997-968986 19971112 (8)
 RLI Continuation of Ser. No. US 1994-276694, filed on 18 Jul 1994, now
 patented, Pat. No. US 5772995
 FS Utility
 INCL Granted
 LN.CNT 1411
 INCLM: 424/093.210
 INCLS: 435/320.100; 435/069.100; 435/325.000; 435/007.230; 435/091.100;
 435/091.400
 NCLM: 424/093.210
 NCLS: 435/007.230; 435/069.100; 435/091.100; 435/091.400; 435/320.100;

IC 435/325.000
 [7]
 ICM: A01N063-00
 EXP 514/44; 424/93.21; 435/320.1; 435/172.3; 435/325; 435/97; 435/62;
 435/71; 435/52; 435/55; 435/69.1; 435/7.23; 435/91.1; 435/91.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 30 USPATFUL.
 AN 2000:109594 USPATFUL.
 TI XAF genes and polypeptides: methods and reagents for modulating
 apoptosis
 IN Korneluk, Robert G., Ottawa, Canada
 PI Tamai, Katsuyuki, Nagano, Japan
 PA Iliston, Peter, Ottawa, Canada
 PI Mackenzie, Alexander B., Ottawa, Canada
 AI Apoptogen Inc., Ottawa, Canada (non-U.S. corporation)
 PRAI US 6107088 20000822
 AI US 1998-100391 19980619 (9)
 AI US 1997-52402P 19970714 (60)
 PRAI US 1997-54491P 19970801 (60)
 US 1997-56338P 19970818 (60)
 DT Utility
 FS Granted
 LN.CNT 4426
 INCLM: 435/325.000
 INCLS: 536/023.100; 536/023.500; 536/024.100; 536/024.500; 435/320.100;
 435/375.000; 435/377.000
 NCLM: 435/325.000
 NCLS: 435/325.000
 IC [7]
 ICM: C12N015-85
 ICS: C12N015-63; C07H021-04
 EXP 435/325; 435/243; 435/410; 435/69.1; 435/69.2; 435/320.1; 435/353;
 435/363; 435/375; 435/377; 536/23.1; 536/23.5; 536/24.5; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 30 USPATFUL.
 AN 1998:75152 USPATFUL.
 TI Compositions and methods for enhanced tumor cell immunity in vivo
 IN Fakhrat, Habib, La Jolla, CA, United States
 PA Dorigo, Oliver, San Diego, CA, United States
 PI Sobol, Robert E., Rancho Santa Fe, CA, United States
 RLI Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S.
 corporation)
 AI US 5772995 19980630
 DT US 1994-276694 19940718 (8)
 FS Utility
 INCL Granted
 LN.CNT 1354
 INCLM: 424/093.210
 INCLS: 435/009.000; 435/007.230; 435/069.100; 435/091.100; 435/091.400;
 435/325.000; 530/389.700
 NCLM: 424/093.210
 NCLS: 435/006.000; 435/007.230; 435/069.100; 435/091.100; 435/091.400;
 435/325.000; 530/389.700
 IC [6]
 ICM: A61K038-54
 EXP 424/93.21; 435/6; 435/7.23; 435/69.1; 435/91.1; 435/91.4; 435/325;
 530/389.7; 935/23; 935/24; 935/52; 935/55; 935/59; 935/62; 935/76;
 935/78
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 30 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2002:281018 BIOSIS
DN PREV200200281018
TI Cellular immunogens comprising cognate proto-oncogenes.
AU Halpern, Michael S (1); England, James M
CS (1) West Newton, MA USA
ASSIGNEE: Philadelphia Health and Educational Corporation, Philadelphia,
PA, USA
PI US 6365151 April 02, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Apr. 2, 2002) Vol. 1257, No. 1, pp. No Pagination.
http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133.
DT Patent
LA English

=> FILE STINGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST 131.90 132.11
FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSENTRUM KARLSRUHE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: JUL 5, 2002 (20020705/UP).

=> d hsl
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS, USPATFULL, BIOSIS' - CONTINUE? (Y)/N:n

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)
FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002
L1 538 S L1 AND ALLOGEN?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998
L5 1 S L2 AND CELL? (A) THERAP?
L6 12 S L1 AND CELL? (A) VACCINE
L7 58 S L1 AND FIBROBLAST
L8 42 S L7 AND ADMINIST?
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)
L10 1688 S CELL? (A) IMMUNOGEN?
L11 30 S L10 AND TRANSENE
FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002

=> FILE MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI
COST IN U.S. DOLLARS
FULL ESTIMATED COST 131.90 132.11

FILE 'MEDLINE' ENTERED AT 09:36:27 ON 11 JUL 2002
FILE 'CANCERLIT' ENTERED AT 09:36:27 ON 11 JUL 2002
FILE 'CAPLUS' ENTERED AT 09:36:27 ON 11 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPATFULL' ENTERED AT 09:36:27 ON 11 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 09:36:27 ON 11 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)
FILE 'EMBASE' ENTERED AT 09:36:27 ON 11 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.
FILE 'CONFSCI' ENTERED AT 09:36:27 ON 11 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

=> d his

(FILE 'HOME' ENTERED AT 09:10:35 ON 11 JUL 2002)
FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:11:14 ON 11 JUL 2002
L1 538 S L1 AND ALLOGEN?
L2 52 S L1 AND ALLOGEN?
L3 27 S L2 AND PROMOT?
L4 11 S L3 NOT PY>1998
L5 1 S L2 AND CELL? (A) THERAP?
L6 12 S L1 AND FIBROBLAST
L7 58 S L1 AND ADMINIST?
L8 42 S L7 AND ADMINIST?
L9 42 DUP REM L8 (0 DUPLICATES REMOVED)
L10 1688 S CELL? (A) IMMUNOGEN?
L11 30 S L10 AND TRANSENE
FILE 'STINGUIDE' ENTERED AT 09:30:40 ON 11 JUL 2002

FILE 'MEDLINE, CANCERLIT, CAPLUS, USPATFULL, BIOSIS, EMBASE, CONFSCI'
ENTERED AT 09:36:27 ON 11 JUL 2002

=> s l10 and oncogene
L12 64 L10 AND ONCOGENE
=> dup rem l12
PROCESSING COMPLETED FOR L12
L13 52 DUP REM L12 (12 DUPLICATES REMOVED)
=> d l13 1-52

L13 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
AN 2002:249967 CAPLUS
DN 136:278130
TI Cellular immunogens comprising cognate proto-
oncogenes for use in cancer vaccines
IN Halpern, Michael S.; England, James M.
PA Philadelphia Health and Educational Corporation, USA
SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 101,226, abandoned.
CODEN: USKXAM
DT Patent
LA English
FAN CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 6365151 B1 20020402 US 1998-167322 19981007
WO 9725860 A1 19970724 WO 1997-US582 19970113
W: AU, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, NO, NZ, PL, PT,
RO, RU, SE, SG, SI, SK, TJ, TM, TR, UA, US, UZ, VN, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RK: KE, LS, MM, SD, SZ, US, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BE, BU, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG
P 19960119
PRAI US 1996-10262P A2 19970113
WO 1997-US582 B2 19980702
US 1998-101226
RE. CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 52 USPTFULL
AN 2002:166378 USPTFULL
TI Minimal adenovirus mediated recombinant vaccine
IN Fang, Xiangming, San Diego, CA, UNITED STATES
Gallichan, Scott, San Diego, CA, UNITED STATES
Zhang, Wei-Wei, San Diego, CA, UNITED STATES
Wong-Straal, Flossie, San Diego, CA, UNITED STATES
Sauter, Sybille, Del Mar, CA, UNITED STATES
PI US 2002088014 A1 20020704
US 2001-974206 A1 20010100 (9)
RLI Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997,
PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan
1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed
on 31 May 1996, PENDING
PRAI US 2000-239224P 20001010 (60)
US 2000-241625P 20001019 (60)
DT Utility
FS APPLICATION
LN. CNT 4062
INCL INCLM: 800/008.000 435/456.000; 435/235.100
INCL INCLM: 800/008.000
NCL NCLM: 800/008.000
NCL NCLM: 435/320.100; 435/456.000; 435/235.100
IC [7]
ICM: A01K067-00
ICS: C12N015-867; C12N015-861; C12N007-00; C12N007-01
L13 ANSWER 3 OF 52 USPTFULL
AN 2002:133493 USPTFULL
TI 98P7C3: homodomain protein highly expressed in various cancers
IN Hubert, Rene S., Los Angeles, CA, UNITED STATES
Fairis, Mary, Los Angeles, CA, UNITED STATES
Afari, Daniel E.H., Brisbane, CA, UNITED STATES
Levin, Eiana, Los Angeles, CA, UNITED STATES
Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
PI US 2002068345 A1 20020606
US 2001-866359 A1 20010524 (9)
PRAI US 2000-207138P 20000524 (60)
DT Utility
FS APPLICATION
LN. CNT 6137
INCL INCLM: 435/183.000
INCL INCLM: 435/325.000; 435/320.100; 435/069.100
NCL INCLM: 435/183.000
NCL NCLM: 435/325.000; 435/320.100; 435/069.100
IC [7]
ICM: C12P021-02
ICS: C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 52 USPTFULL
AN 2002:106269 USPTFULL
TI GTP-binding protein useful in treatment and detection of cancer
IN Fairis, Mary, Los Angeles, CA, UNITED STATES
Challita-Eid, Pia M., Encino, CA, UNITED STATES
Raitano, Arthur B., Los Angeles, CA, UNITED STATES
Mitchell, Steve Chappell, Santa Monica, CA, UNITED STATES
Afari, Daniel E.H., Brisbane, CA, UNITED STATES
Jakobovits, Aya, Beverly Hills, CA, UNITED STATES
PI US 2002055478 A1 20020509
US 2001-834765 A1 20010412 (9)
PRAI US 2000-19647P 20000412 (60)
DT Utility
FS APPLICATION
LN. CNT 5003
INCL INCLM: 514/044.000
INCL INCLM: 435/006.000; 435/007.230
NCL INCLM: 514/044.000
NCL NCLM: 435/006.000; 435/007.230
IC [7]
ICM: A61K039-00
ICS: C12N001-68; G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 52 USPTFULL
AN 2002:84909 USPTFULL
TI Methods and compositions for co-stimulation of immunological responses
IN Kneif, Samir, Silver Spring, MD, UNITED STATES
Berzofsky, Jay, Bethesda, MD, UNITED STATES
PI US 2002044948 A1 20020418
US 2001-810310 A1 20010314 (9)
PRAI US 2000-18936P 20000315 (60)
DT Utility
FS APPLICATION
LN. CNT 3104
INCL INCLM: 424/234.100
INCL INCLM: 424/184.100; 530/350.000
NCL INCLM: 424/234.100
NCL NCLM: 424/184.100; 530/350.000
IC [7]
ICM: A61K039-00
ICS: A61K039-38; A61K039-02; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 52 USPTFULL
AN 2002:43212 USPTFULL
TI Formulations for electroporation
IN MacLaughlin, Fiona, Belfast, UNITED KINGDOM
Li, Shulin, The Woodlands, TX, UNITED STATES
Li, Yuhua, The Woodlands, TX, UNITED STATES
Petrak, Karel, Spring, TX, UNITED STATES
PA Valentis, Inc., The Woodlands, TX (non-U.S. corporation)
PI US 2002025578 A1 20020228
US 2001-903009 A1 20010710 (9)
RLI Continuation of Ser. No. US 1999-322602, filed on 28 May 1999, PENDING
PRAI US 1998-88691P 19980608 (60)
DT Utility
FS APPLICATION
LN. CNT 1353
INCL INCLM: 435/463.000
INCL INCLM: 435/463.000
IC [7]

ICM: C12N015-87
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 52 USPATFULT
 AN 2002:16585 USPATFULT
 TI Porcine neural cells and their use in treatment of neurological deficits
 IN due to neurodegenerative diseases
 PA Traccon, Ole, Cambridge, MA, UNITED STATES
 PI Diacrin, Inc. (U.S. Corporation)
 AI US 2002009461 A1 20020124
 RLI US 2001-847881 A1 20010502 (9)
 Division of Ser. No. US 1995-554779, filed on 7 Nov 1995, GRANTED. Pat.
 No. US 628353 Continuation-in-part of Ser. No. US 1995-424851, filed on
 19 Apr 1995, GRANTED. Pat. No. US 6294383 Continuation-in-part of Ser.
 No. US 1994-336856, filed on 8 Nov 1994, ABANDONED

DT Utility
 PS APPLICATION

LN.CNT 5037
 INCL INCLM: 424/193.100
 INCLS: 424/093.700; 435/325.000
 NCL NCLM: 424/193.100
 NCLS: 424/093.700; 435/325.000

IC [7]
 ICM: A61K039-385
 ICS: C12N005-06; A61K045-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 52 USPATFULT
 AN 2002:144239 USPATFULT
 TI Tumor antigens and CTL clones isolated by a novel procedure
 IN Luftein, Rosalie, Brussels, BELGIUM
 Dufour, Marie-Therese, Brussels, BELGIUM
 Demotte, Nathalie, Brussels, BELGIUM
 van der Brugan, Pierre, Brussels, BELGIUM
 Cornelius, Guy, Brussels, BELGIUM
 Stroobant, Vincent, Brussels, BELGIUM
 Lurquin, Christophe, Brussels, BELGIUM
 Boon-Falleur, Thierry, Brussels, BELGIUM
 Ludwig Institute for Cancer Research, New York, NY, United States (U.S.
 corporation)
 PA Universite Catholique de Louvain, Louvain-la-Neuve, BELGIUM (non-U.S.
 corporation)
 PI US 6407063 B1 20020618
 AI US 1998-165863 19981002 (9)
 DT Utility
 PS GRANTED

LN.CNT 1456
 INCL INCLM: 514/013.000
 INCLS: 530/326.000; 530/328.000; 514/015.000
 NCL NCLM: 514/013.000
 NCLS: 530/326.000; 530/328.000; 514/015.000

IC [7]
 ICM: A61K038-08
 ICS: A61K038-10; C07K007-06; C07K007-08
 514/15; 514/13; 530/328; 530/326
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

EXF 514/15; 514/13; 530/328; 530/326
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 52 USPATFULT
 AN 2002:116068 USPATFULT
 TI Recombinant alphavirus-based vectors with reduced inhibition of cellular
 macromolecular synthesis
 IN Dubensky, Jr., Thomas W., Del Mon, CA, United States
 Polo, John W., Encinitas, CA, United States

PA Belli, Barbara A., San Diego, CA, United States
 Schlesinger, Sondra, St. Louis, MO, United States
 Dryga, Sergey A., Fort Collins, CO, United States
 Frolov, Ilya, St. Louis, MO, United States
 Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI Washington University, St. Louis, MO, United States (U.S. corporation)
 AI US 6391632 B1 20020521
 US 1999-415784 19991008 (9)
 Division of Ser. No. US 1997-944465, filed on 6 Oct 1997
 Continuation-in-part of Ser. No. US 1997-83148, filed on 4 Apr 1997,
 now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on
 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US
 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of
 Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned

DT Utility
 PS GRANTED

LN.CNT 8166
 INCL INCLM: 435/325.000
 INCLS: 435/069.100; 435/457.000; 536/023.720
 NCL NCLM: 435/325.000
 NCLS: 435/069.100; 435/457.000; 536/023.720

IC [7]
 ICM: C12N005-10
 EXF 435/325; 435/69.1; 435/457; 536/23.72
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 52 USPATFULT
 AN 2002:19216 USPATFULT
 TI Nucleotide and deduced amino acid sequences of tumor gene Int6
 IN Marchetti, Antonio, Viareggio, ITALY
 Buttila, Fiama, Viareggio, ITALY
 Smith, Gilbert H., Falls Church, VA, United States
 Callahan, Robert, Alexandria, VA, United States
 The United States of America, as represented by the Department of Health
 and Human Services, Washington, DC, United States (U.S. corporation)
 PA US 6342392 B1 20020129
 US 1999-378842 19990823 (9)
 Division of Ser. No. US 875847 Continuation-in-part of Ser. No. US
 1995-385998, filed on 9 Feb 1995, now abandoned

DT Utility
 PS GRANTED

LN.CNT 2076
 INCL INCLM: 436/063.000
 INCLS: 436/086.000; 435/006.000
 NCL NCLM: 436/063.000
 NCLS: 435/006.000; 436/086.000

IC [7]
 ICM: G01N033-48
 ICS: G01N033-00; C12Q001-68
 514/12; 436/63; 436/86; 435/6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

EXF 514/12; 436/63; 436/86; 435/6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 52 USPATFULT
 AN 2002:13790 USPATFULT
 TI Superantigen based methods and compositions for treatment of diseases
 IN Terman, David Stephen, 3183 Palermo Way, Pebble Beach, CA, United States
 PI US 6340461 B1 20020122
 AI US 1997-992877 19971217 (8)
 PRAI US 1996-33172P 19961217 (60)
 US 1997-44074P 19970417 (60)

DT Utility
 PS GRANTED

LN.CNT 5893

INCL INCLM: 424/193.100
 INCLS: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700
 NCLM: 424/193.100
 NCLM: 424/192.100; 424/194.100; 424/277.100; 424/278.100; 424/280.100;
 424/282.100; 435/068.100; 435/069.100; 435/069.300; 435/069.700
 IC [7]
 ICM: A61K039-385
 ICS: A61K039-00; A61K039-39; A61K045-00; C12N015-09; C12N015-12;
 C12N015-62; C12N015-63
 EXP 424/277.1; 424/193.1; 424/194.1; 424/192.1; 424/278.1; 424/280.1;
 424/282.1; 435/68.1; 435/69.7; 435/69.3; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 52 USPATFULT
 AN 2002:9741 USPATFULT
 TI Method for identifying cytotoxic T-cell epitopes
 IN Nicolette, Charles A., Marlborough, MA, United States
 PA Genzyme Corporation, Framingham, MA, United States (U.S. corporation)
 PI US 6338945 B1 20020115
 PI US 1997-989195 19971211 (8)
 RLI Continuation of Ser. No. MO 1997-US4479, filed on 20 Mar 1997
 PRAI US 1996-13706P 19960320 (60)
 DT Utility
 FS GRANTED
 LN CNT 1648
 INCL INCLM: 435/007.100
 INCLS: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 530/300.000;
 530/328.000; 436/518.000
 NCLM: 435/007.100
 NCLM: 435/004.000; 435/DIG.001; 435/DIG.015; 435/DIG.035; 436/518.000;
 530/300.000; 530/328.000
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-543; A61K038-00
 EXP 530/300; 530/327; 530/328; 530/333; 530/334; 530/335; 436/518; 436/501;
 436/524; 435/77.1; 435/DIG.1; 435/DIG.2; 435/DIG.14; 435/DIG.15;
 435/DIG.22; 435/DIG.34; 435/DIG.35; 435/DIG.21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 52 USPATFULT
 AN 2001:212422 USPATFULT
 TI Treatment of allergies
 IN Levy, Shoshana, Stanford, CA, United States
 Dekruyff, Rosemarie H., Stanford, CA, United States
 Umesu, Hiden, Mountain View, CA, United States
 PI US 2001044418 A1 20011122
 AI US 2001-798075 A1 20010302 (9)
 PRAI US 2000-188311P 20000310 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1218
 INCL INCLM: 514/044.000
 INCLS: 424/085.200
 NCLM: 514/044.000
 NCLM: 514/044.000
 NCLM: 424/085.200
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-20
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 52 USPATFULT
 AN 2001:199741 USPATFULT

TI Cancer immunotherapy using autologous tumor cells combined with cells
 expressing a membrane cytokine
 IN Hiserodt, John C., Huntington Beach, CA, United States
 Graf, Martin R., Richmond VA, United States
 PI Granger, Gale A., Laguna Beach, CA, United States
 AI US 2001038841 A1 20011108
 RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
 PRAI No. US 6277368
 US 1996-23108P 19960725 (60)
 DT US 1996-29286P 19961029 (60)
 FS APPLICATION
 LN CNT 2638
 INCL INCLM: 424/130.100
 INCLS: 424/277.100; 435/368.000
 NCLM: 424/130.100
 NCLM: 424/277.100; 435/368.000
 IC [7]
 ICM: A61K039-395
 ICS: A61K039-00; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 52 USPATFULT
 AN 2001:193945 USPATFULT
 TI Cancer immunotherapy using autologous tumor cells combined with cells
 expressing a membrane cytokine
 IN Hiserodt, John C., Huntington Beach, CA, United States
 Graf, Martin R., Richmond, VA, United States
 PI Granger, Gale A., Laguna Beach, CA, United States
 AI US 2001036458 A1 20011101
 RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
 PRAI No. US 6276923
 US 1996-23108P 19960725 (60)
 DT US 1996-29286P 19961029 (60)
 FS APPLICATION
 LN CNT 2634
 INCL INCLM: 424/130.100
 INCLS: 424/277.100; 435/368.000
 NCLM: 424/130.100
 NCLM: 424/277.100; 435/368.000
 IC [7]
 ICM: A61K039-395
 ICS: A61K039-00; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 52 USPATFULT
 AN 2001:167936 USPATFULT
 TI Hepatitis therapeutics
 IN Jolly, Douglas J., Leucadia, CA, United States
 Chang, Stephen M. W., Poway, CA, United States
 Lee, William T. L., Carlsbad, CA, United States
 Townsend, Kay, Encinitas, CA, United States
 O'Dea, Joanne, La Jolla, CA, United States
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
 PI US 6297048 19950607 (8)
 AI US 1995-483511 20011002
 RLI Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,
 now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on
 5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US
 1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of
 Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned

Continuation-in-part of Ser. No. US 1992-810417, filed on 4 Feb 1992,
now abandoned

DT Utility
FS GRANTED
LN.CNT 3732
INCL INCLM: 435/320.100
NCLM: 435/069.300
NCL INCLM: 435/320.100
NCLM: 435/069.300
IC [7]
ICM: C12N015-63
ICS: C12P021-02
EXF 435/69.1; 435/69.3; 435/320.1; 424/228.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 52 USPTAFULL
AN 2001:136177 USPTAFULL
TI Cancer immunotherapy using autologous tumor cells combined with cells
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
The Regents of the University of California, Oakland, CA, United States
PA (U.S. Corporation) B1 20010821
PI US 6277368
AI US 1997-801225 19970724 (8)
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS GRANTED
LN.CNT 2892
INCL INCLM: 424/093.210
NCLM: 424/093.100; 424/093.300; 424/093.700; 424/093.710; 424/085.100;
424/085.200; 424/085.600; 424/277.100; 435/325.000
NCL INCLM: 424/093.210
NCLM: 424/085.100; 424/085.200; 424/085.600; 424/093.100; 424/093.300;
424/093.700; 424/093.710; 424/277.100; 435/325.000
IC [7]
ICM: A01N063-00
ICS: C12N015-85; A61K035-12; A61K035-19
424/93.21; 424/93.1; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;
424/85.4; 424/277.1; 435/325
EXF 424/93.1; 424/93.2; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;
424/85.4; 424/277.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 52 USPTAFULL
AN 2001:107439 USPTAFULL
TI Porcine neural cells and their use in treatment of neurological deficits
IN due to neurodegenerative diseases
Isacson, Ole, Cambridge, MA, United States
Dinmore, Jonathan, Brookline, MA, United States
Diachin, Inc., Charlestown, MA, United States (U.S. Corporation)
PI US 6258353 B1 20010710
AI US 1995-554779 19951107 (8)
RLI Continuation-in-part of Ser. No. US 1995-424851, filed on 19 Apr 1995
now abandoned
DT Utility
FS GRANTED
LN.CNT 5157
INCL INCLM: 424/093.100
NCLM: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;
435/368.000
NCLM: 424/093.100
NCLM: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;
435/368.000
NCLM: 424/093.100
NCLM: 424/093.700; 424/130.100; 424/143.100; 424/809.000; 435/325.000;

IC [7] 435/368.000
ICM: A01N003-00
ICS: C12N015-85; C12N015-86; A61K039-395
424/93.7; 424/93.1; 424/130.1; 424/143.1; 424/809.000; 435/325.000;
435/368.000
EXF 424/93.1; 424/93.2; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;
424/85.4; 424/277.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 52 USPTAFULL
AN 2001:102615 USPTAFULL
TI Nucleotide and deduced amino acid sequences of tumor gene int6
IN Marchetti, Antonio, Viareggio, Italy
Butticci, Fiama, Viareggio, Italy
Smith, Gilbert H., Falls Church, VA, United States
Callahan, Robert, Alexandria, VA, United States
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. Government)
PI US 6255105 B1 20010703
PRAI US 1997-875847 19970925 (8)
US 1997-875847 19960209
WO 1996-US1884 19970925 PCT 371 date
19970925 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-385998, filed on 9 Feb 1995,
now abandoned
DT Utility
FS GRANTED
LN.CNT 1789
INCL INCLM: 435/325.000
NCLM: 435/252.300; 435/320.100; 435/069.100
NCL INCLM: 435/252.300; 435/325.000
NCLM: 435/069.100; 435/252.300; 435/320.100
IC [7]
ICM: C12N005-00
ICS: C12N015-00; C12N001-20; C12P021-06
435/69.1; 435/320.1; 435/325.000; 435/252.3; 435/366; 435/371; 435/252.8
EXF 435/69.1; 435/320.1; 435/325.000; 435/252.3; 435/366; 435/371; 435/252.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 52 USPTAFULL
AN 2001:67168 USPTAFULL
TI Cancer therapy using an oncogene product and a foreign MHC
IN molecule
Maudeley, David John, 18 Common Lane, Kenilworth, Warwickshire CV8 2PR,
United Kingdom
PI US 6228357 B1 20010508
AI US 1999-269686 19990330 (9)
US 1999-269686 19970930
WO 1997-GB2691 19990330 PCT 102(e) date
19960930
PRAI GB 1996-20350 19960930
DT Utility
FS GRANTED
LN.CNT 330
INCL INCLM: 424/093.200
NCLM: 424/093.100; 424/093.210; 424/325.000
NCL INCLM: 424/093.200
NCLM: 424/093.100; 424/093.210; 435/325.000
IC [7]
ICM: C12N015-85
ICS: C12N015-80
424/93.1; 424/325; 424/93.2; 424/93.21
EXF 424/93.1; 424/325; 424/93.2; 424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 52 USPTAFULL

AN 2001:55742 USPATFULTL
 TI Adjuvant incorporation into antigen carrying cells: compositions and
 methods
 IN Ravindranath, Mepur H., Los Angeles, CA, United States
 Morcon, Donald L., Malibu, CA, United States
 PA John Wayne Cancer Institute, Santa Monica, CA, United States (U.S.
 corporation)
 PI US 6218166 B1 20010417
 AI US 1995-462106 19950605 (8)
 RLI Continuation-in-part of Ser. No. US 1994-353549, filed on 9 Dec 1994,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 5039
 INCL INCLM: 435/240.200
 INCLS: 424/240.100; 424/277.100; 424/283.100; 424/184.100; 424/078.310;
 424/278.100; 424/179.100; 424/174.100; 424/150.100; 424/201.100
 NCLM: 435/366.000
 NCLS: 424/078.310; 424/150.100; 424/174.100; 424/179.100; 424/184.100;
 424/201.100; 424/240.100; 424/277.100; 424/278.100; 424/283.100;
 435/325.000; 435/354.000; 435/372.000
 IC [7]
 ICM: A61K039-00
 ICS: A61K045-00; A61K039-40; A61K039-395
 EXF 424/240.1; 424/277.1; 424/283.1; 424/184.1; 424/78.31; 424/278.1;
 424/179.1; 424/150.1; 424/201.1; 424/174.1; 435/240.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 52 USPATFULTL
 AN 2001:33252 USPATFULTL
 TI Compositions and methods for delivery of genetic material
 IN Carrano, Richard A., Paoli, PA, United States
 Wang, Bin, Haidian, China
 Weiner, David B., Merion, PA, United States
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United
 States (U.S. corporation)
 PI Apollan, Inc., Malvern, PA, United States (U.S. corporation)
 AI US 6197755 B1 20010306 (9)
 RLI Continuation of Ser. No. US 704701, now patented, Pat. No. US 5962428
 patented, Pat. No. US 5739118, issued on 14 Apr 1998
 DT Utility
 FS Granted
 LN.CNT 3329
 INCL INCLM: 514/044.000
 INCLS: 424/278.100
 NCLM: 514/044.000
 NCLS: 424/278.100
 IC [7]
 ICM: A61K031-7088
 ICS: A61K045-05
 EXF 424/93.1; 424/278.1; 435/69.1; 435/320.1; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 52 USPATFULTL
 AN 2001:21755 USPATFULTL
 TI Cancer immunotherapy with semi-allogeneic cells
 IN Cohen, Edward F., Chicago, IL, United States
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
 corporation)
 PI US 6187307 B1 20010213
 AI US 1998-16528 19980130 (9)
 PRAI US 1997-36620P 19970131 (60)

DT Utility
 FS Granted
 LN.CNT 2184
 INCL INCLM: 424/093.210
 INCLS: 424/093.710; 435/455.000; 435/372.000; 435/366.000; 435/325.000;
 536/023.500
 NCLM: 424/093.210
 NCLS: 424/093.710; 435/325.000; 435/366.000; 435/372.000; 435/455.000;
 536/023.500
 IC [7]
 ICM: C12N005-10
 ICS: C12N005-08; A01N063-00
 EXF 435/325; 435/455; 435/366; 435/372; 424/93.21; 424/93.71; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:84650 CAPLUS
 DN 132:136415
 TI Allogeneic cellular immunogens useful as cancer
 vaccines
 IN Halpern, Michael S.; England, James M.
 PA Allegheny University of the Health Sciences, USA
 SO PCT Int. Appl. 77 pp.
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200004927	A1	20000203	WO 1999-US15594	19990708
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MM, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU,				
HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL, PT, RO,				
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US, UZ, VN,				
YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK,				
EE, ES, FI, FR, GB, GR, GU, HE, HI, HR, HU, IL, IN, IS, JP, KE,				
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
MM, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
TM, TR, TT, UA, UC, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR,				
CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GD, GE, GH, GM,				
GR, GU, HA, HE, HI, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MN, MX, MY, NZ, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UC, US,				
UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, FR, GB, GR, GU, HA, HE, HI, HR, HU, IL, IN, IS,				
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
MN, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				

IC NCLs: 424/093.700; 435/374.000
 (7)
 ICM: C12N005-00
 EXP 435/325: 435/374; 435/93.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 52 USPATFULT
 AN 2000:117521 USPATFULT
 TI DNA encoding density enhanced protein tyrosine phosphatases
 IN Tonks, Nicholas K., Huntington, NY, United States
 Ostman, Arne, Uppsala, Sweden
 PA Cold Spring Harbor Laboratory, United States (U.S. corporation)
 PI US 6114140
 AI US 1997-854585 20000905
 RLI Continuation of Ser. No. US 1994-237940, filed on 3 May 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1539
 INCL INCLM: 435/069.100
 INCLS: 435/196.000; 435/325.000; 435/252.300; 435/254.110; 435/320.100;
 435/471.000; 536/023.500; 536/024.310; 536/024.310; 530/350.000
 NCLM: 435/069.100
 NCLS: 435/196.000; 435/325.300; 435/254.110; 435/320.100; 435/325.000;
 435/471.000; 530/350.000; 536/023.500; 536/024.300; 536/024.310

IC (7)
 ICM: C12N015-52
 ICS: C12N015-63; C12N005-10
 EXP 435/69.1; 435/196; 435/325; 435/252.3; 435/254.11; 435/320.1; 435/471;
 536/23.5; 536/24.3; 536/24.11; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 27 OF 52 USPATFULT
 AN 2000:109594 USPATFULT
 TI XAF genes and polypeptides: methods and reagents for modulating
 IN apoptosis
 Korneluk, Robert G., Ottawa, Canada
 Tamai, Katsuyuki, Nagano, Japan
 Liston, Peter, Ottawa, Canada
 PA MacKenzie, Alexander E., Ottawa, Canada
 PI US 6107088 20000822
 AI US 1998-100391 19980619 (9)
 PRAI US 1997-52402P 19970714 (60)
 US 1997-54481P 19970801 (60)
 US 1997-56338P 19970818 (60)
 DT Utility
 FS Granted
 LN.CNT 4426
 INCL INCLM: 435/325.000
 INCLS: 536/023.100; 536/023.500; 536/024.100; 536/024.500; 435/320.100;
 435/375.000; 435/377.000
 NCLM: 435/325.000
 NCLS: 435/320.100; 435/375.000; 435/377.000; 536/023.100; 536/023.500;
 536/024.100; 536/024.500

IC (7)
 ICM: C12N015-85
 ICS: C12N015-63; C07H021-04
 EXP 435/325; 435/243; 435/410; 435/69.1; 435/69.2; 435/320.1; 435/353;
 435/363; 435/375; 435/377; 536/23.1; 536/23.5; 536/24.5; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 28 OF 52 USPATFULT
 AN 2000:70820 USPATFULT

TI Insulin-like growth factor 1 receptors (IGF-IR) antisense
 IN oligonucleotide cell composition
 Low, Walter C., Shorewood, MN, United States
 Mallenfriedman, Margaret A., Edina, MN, United States
 Chiang, Ian, Plymouth, MN, United States
 PA Regents of the University of Minnesota, Minneapolis, MN, United States
 PI US 6071891 20000606
 AI US 1996-755558 19961122 (8)
 DT Utility
 FS Granted
 LN.CNT 999
 INCL INCLM: 514/044.000
 INCLS: 424/277.100; 435/006.000; 435/320.100; 435/325.000; 435/353.000;
 514/044.000; 536/023.100; 536/024.310; 536/024.500
 NCLM: 514/044.000
 NCLS: 424/277.100; 435/006.000; 435/320.100; 435/325.000; 435/353.000;
 536/023.100; 536/024.310; 536/024.500

IC (7)
 ICM: A61K048-00
 ICS: A61K035-12; C12N015-85; C07H021-04
 EXP 435/6; 435/91.1; 435/172.1; 435/440; 435/320.1; 435/353; 435/325;
 536/23.1; 536/24.31; 536/24.5; 514/44; 424/274.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 29 OF 52 USPATFULT
 AN 2000:61176 USPATFULT
 TI Method for determining oncogenic activity of a substance
 IN Schreiber, Robert, St. Louis, MO, United States
 Old, Lloyd J., New York, NY, United States
 PA Washington University, St. Louis, MO, United States (U.S. corporation)
 PI US 6063359 20000516
 AI US 1997-938295 19970926 (8)
 DT Utility
 FS Granted
 LN.CNT 1072
 INCL INCLM: 424/009.200
 INCLS: 424/009.100; 424/277.100; 424/093.100; 800/003.000; 800/008.000;
 800/018.000; 800/014.000
 NCLM: 424/009.200
 NCLS: 424/009.100; 424/093.100; 424/277.100; 800/003.000; 800/008.000;
 800/014.000; 800/018.000

IC (7)
 ICM: C12N005-00
 ICS: A61K049-00
 EXP 800/3; 800/8; 800/18; 800/14; 424/93.1; 424/93.21; 424/277.1; 424/9.1;
 424/9.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 30 OF 52 USPATFULT
 AN 2000:1745 USPATFULT
 TI Antibody heteroconjugates and bispecific antibodies for use in
 IN regulation of lymphocyte activity
 Isobetter, Jeffrey A., Seattle, WA, United States
 Gilliland, Lisa K., Seattle, WA, United States
 PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
 PI US 6010902 20000104
 AI US 1994-366401 19941229 (8)
 RLI Continuation of Ser. No. US 1993-28527, filed on 9 Mar 1993, now abandoned which is a continuation of Ser. No. US 1992-880307, filed on 5 May 1992, now abandoned which is a continuation of Ser. No. US 1991-733369, filed on 19 Jul 1991, now abandoned which is a continuation of Ser. No. US 1989-424801, filed on 20 Oct 1989, now abandoned which is

a continuation-in-part of Ser. No. US 1988-271934, filed on 14 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-176825, filed on 4 Apr 1988, now abandoned

DT Utility Granted

FS Granted

LN CNT 2714

INCL INCLM: 435/328.000

NCL INCLM: 435/332.000; 435/334.000; 530/388.750; 530/391.100; 530/405.000; 530/387.300

NCLM: 435/328.000

NCL: 435/332.000; 435/334.000; 530/387.300; 530/388.750; 530/391.100; 530/405.000

IC [6]

ICM: C12N005-00

EXF ICS: C12N005-02; C07K016-00; C12P021-08

424/144.1; 424/179.1; 435/240.27; 435/328; 435/332; 435/334; 530/388.75; 530/391.1; 530/405; 530/387.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.

TI Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

AU Dakapagari N.K.; Douglas D.B.; Trilozzi P.L.; Stevens V.C.; Kamaya P.T.P.

CS P.T.P. Kamaya, Ohio State University, Comprehensive Cancer Center, 410 West 12th Avenue, Columbus, OH 43210, United States. Kamaya.1@osu.edu

SO Cancer Research, (15 Jul 2000) 60/14 (3782-3789).

Refs: 63

ISSN: 0008-5472 CODEN: CNRBA8

CY United States

DT Journal: Article

FS 016 Cancer

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LA English

SL English

L13 ANSWER 32 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.

TI Differential expression of intracisternal A-particle transcripts in immunogenic versus tumorigenic S49 murine lymphoma cells.

AU Braun E.; Borman E.; Lueders K.K.; Bar-Sinai A.; Hochman J.

CS J. Hochman, Dept. of Cell and Animal Biology, Hebrew University of Jerusalem, Jerusalem 91904, Israel. hochman@ms.huji.ac.il

SO Virology, (10 Nov 2000) 277/1 (136-146).

Refs: 40

ISSN: 0042-6822 CODEN: VIRLAX

CY United States

DT Journal: Article

FS 026 Immunology, Serology and Transplantation

LA English

SL English

L13 ANSWER 33 OF 52 USPTFULL

TI 1999:141912 USPTFULL

TI Compositions and methods for delivery of genetic material

Werner, David B.; Merion, PA, United States

Williams, William V.; Havertown, PA, United States

Wang, Bin; Havertown, PA, United States

PA The Trustees of The University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

TI The Mistr Institute, Philadelphia, PA, United States (U.S. corporation)

US 5981505 19991109

PI WO 9416737 19940804

AI US 1997-979385 19971126 (8)

MO 1994-US899 19940126

19950828 PCT 371 date

19950828 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1993-124962, filed on 21 Sep 1993, now abandoned And a continuation-in-part of Ser. No. US 1993-93335, filed on 15 Jul 1993, now abandoned And a continuation of Ser. No. US 1995-495684, filed on 28 Aug 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-125012, filed on 21 Sep 1993, now patented. Pat. No. US 5593972, issued on 14 Jan 1997 which is a continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned

DT Utility Granted

FS Granted

LN CNT 4084

INCL INCLM: 514/044.000

NCL INCLM: 424/278.100; 514/615.000; 514/818.000

NCLM: 514/044.000

NCL: 424/278.100; 514/615.000; 514/818.000

IC [6]

ICM: A61K045-05

EXF ICS: A61K045-00; A61K031-00

514/44; 514/615; 514/818; 435/320.1; 435/93.1; 435/93.2; 435/93.21; 435/975; 424/278.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 52 USPTFULL

TI 1999:141300 USPTFULL

TI Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis

IN Avraham, Hava; Brookline, MA, United States

PA Groopman, Jerome E.; Brookline, MA, United States

US (U.S. corporation)

PI US 5980893 19991109

DT US 1997-895626 19970717 (8)

FS Utility Granted

LN CNT 969

INCL INCLM: 424/144.100

NCL INCLM: 424/133.100; 424/135.100; 424/142.100; 424/143.100; 424/153.100; 424/178.100; 424/093.700; 435/076.210; 435/334.000; 435/343.000; 530/387.300; 530/388.150; 530/388.200; 530/388.220; 530/388.700; 530/389.600; 530/391.100

NCLM: 424/093.700; 424/133.100; 424/135.100; 424/142.100; 424/143.100; 424/153.100; 424/178.100; 435/076.210; 435/334.000; 435/343.000; 530/387.300; 530/388.150; 530/388.200; 530/388.220; 530/388.700; 530/389.600; 530/391.100

NCL: 424/133.100; 424/135.100; 424/142.100; 424/143.100; 424/153.100; 424/178.100; 435/076.210; 435/334.000; 435/343.000; 530/387.300; 530/388.150; 530/388.200; 530/388.220; 530/388.700; 530/389.600; 530/391.100

IC [6]

ICM: C07K016-28

EXF ICS: C12N005-12

424/93.7; 424/133.1; 424/135.1; 424/142.1; 424/143.1; 424/144.1; 424/153.1; 424/178.1; 435/70.21; 435/334; 435/343; 530/387.3; 530/388.15; 530/388.2; 530/388.22; 530/388.7; 530/389.6; 530/391.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 52 USPTFULL

TI 1999:121330 USPTFULL

TI Compositions and methods for delivery of genetic material

Carino, Richard A.; Paoli, PA, United States

Wang, Bin; Haidian, China

Werner, David B.; Merion, PA, United States

PA Apollon, Inc., Malvern, PA, United States (U.S. corporation)
The Trustees of The University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5964248 19991005
WO 9526718 19951012
US 1996-704701
MO 1995-US4071
AI 19960916 (8)
19950330
19960916 PCT 371 date
19960916 PCT 102(e) date

RLI Continuation of Ser. No. US 221579
FS Utility
LN.CNT 2276
INCL INCLM: 530/387.100
INCLM: 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.800;
NCLM: 530/387.100
NCLM: 530/387.100
NCLM: 435/069.700; 435/070.210; 435/172.100; 435/326.000; 530/387.300;
NCLM: 530/388.100; 530/388.200; 530/388.800
IC [6]
ICM: C07K016-00
ICS: C12N005-00; C12N015-00; C12P021-04
530/387.1; 530/387.3; 530/387.7; 530/388.1; 530/388.2; 530/388.8;
435/69.7; 435/70.21; 435/172.1; 435/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 52 USPTAFULL
AN 1999:106325 USPTAFULL
TI Nucleic acids encoding antigen-binding sites specific for cancer
IN antitigens
PA King, David B., Palo Alto, CA, United States
PI Chilton Corporation, Emeryville, CA, United States (U.S. corporation)
US 5948647 19990907
US 1995-484508 19950607 (8)
AI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994,
now abandoned which is a continuation of Ser. No. US 1993-141375, filed
on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US
1990-605399, filed on 29 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2409
INCL INCLM: 435/069.600
INCLM: 435/023.530; 435/070.210; 435/455.000; 435/328.000; 435/326.000;
435/330.000; 435/344.000; 435/346.000; 435/330.100; 530/387.700;
530/388.800; 530/389.700; 424/133.100; 424/138.100; 424/155.100;
424/174.100
NCLM: 435/069.600
NCLM: 424/133.100; 424/138.100; 424/155.100; 424/174.100; 435/070.210;
435/320.100; 435/326.000; 435/328.000; 435/330.000; 435/344.000;
435/346.000; 435/455.000; 530/387.700; 530/388.800; 530/389.700;
536/023.530
IC [6]
ICM: C12N015-06
ICS: C12N015-13; A61K039-395
424/138.1; 424/143.1; 424/138.1; 424/138.1; 424/85.1; 424/93.7; 424/133.1;
424/155.1; 424/174.1; 536/23.53; 435/69.6; 435/252.3; 435/240.22;
435/70.21; 435/455; 435/328; 435/326; 435/330; 435/344; 435/346;
435/320.1; 530/387.7; 530/388.8; 530/389.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 37 OF 52 USPTAFULL
AN 1998:157476 USPTAFULL
TI Antigen-binding sites of antibody molecules specific for cancer antigens
IN King, David B., Palo Alto, CA, United States
PA Chilton Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 5849877 19981215
US 1995-483199 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994,
now abandoned which is a continuation of Ser. No. US 1993-141375, filed
on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US
1990-605399, filed on 29 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2276
INCL INCLM: 530/387.100
INCLM: 530/387.300; 530/387.700; 530/388.100; 530/388.200; 530/388.800;
NCLM: 530/387.100
NCLM: 530/387.100
NCLM: 435/069.700; 435/070.210; 435/172.100; 435/326.000; 530/387.300;
530/388.100; 530/388.200; 530/388.800
IC [6]
ICM: C07K016-00
ICS: C12N005-00; C12N015-00; C12P021-04
530/387.1; 530/387.3; 530/387.7; 530/388.1; 530/388.2; 530/388.8;
435/69.7; 435/70.21; 435/172.1; 435/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 38 OF 52 USPTAFULL
AN 1998:135023 USPTAFULL
TI Genetic immunization
IN Weiner, David B., Merion, PA, United States
PA Williams, William V., Havertown, PA, United States
PI Wang, Bin, Havertown, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
AI US 5830876 19981103
US 1995-453349 19950530 (8)
AI Continuation of Ser. No. US 1993-29336, filed on 11 Mar 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1993-8342,
filed on 26 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2955
INCL INCLM: 514/044.000
INCLM: 424/278.100; 514/615.000; 514/818.000
NCLM: 514/044.000
NCLM: 514/044.000
IC [6]
ICM: A61K045-05
ICS: A61K048-00; A61K031-00
435/320.1; 424/93.1; 424/93.2; 424/93.21; 424/278.1; 514/44; 514/615;
514/818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 39 OF 52 USPTAFULL
AN 1998:122388 USPTAFULL
TI Genetic immunization
IN Weiner, David B., Merion, PA, United States
PA Williams, William V., Havertown, PA, United States
PI Wang, Bin, Havertown, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
AI US 5817637 19981006
US 1997-783818 19970113 (8)
AI Continuation of Ser. No. US 1993-125012, filed on 21 Sep 1993, now
patented, Pat. No. US 5993972, issued on 14 Jan 1997 which is a
continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993,
now abandoned which is a continuation-in-part of Ser. No. US 1993-8342,
filed on 26 Jan 1993, now abandoned

DT Utility
FS Granted
LN.CNT 3641
INCL INCLM: 514/044.000
NCL INCLS: 424/278.100; 435/975.000; 514/044.000; 514/615.000; 514/818.000
NCLM: 514/044.000
NCLS: 424/278.100; 435/975.000; 514/615.000; 514/818.000
IC [6]
ICM: A61K045-05
EXP ICS: A61K048-00; A61K031-00
514/44; 514/615; 514/818; 424/278.1; 435/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 40 OF 52 USPTFULT
AN 1998:115563 USPTFULT
TI Isolated nucleic acid molecules encoding antigen binding sites of
IN antibody molecules specific for cancer antigens
PA King, David B., Palo Alto, CA, United States
PI Chilton Corporation, Emeryville, CA, United States (U.S. corporation)
US 5811267 19980922
PI US 1995-475000 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-323566, filed on 17 Oct 1994,
now abandoned which is a continuation of Ser. No. US 1993-141375, filed
on 22 Oct 1993, now abandoned which is a continuation of Ser. No. US
1990-605399, filed on 29 Oct 1990, now abandoned

DT Utility
FS Granted
LN.CNT 2280
INCL INCLM: 435/069.700
NCL INCLS: 435/070.210; 435/172.100; 435/172.300; 536/023.100; 536/023.400;
530/387.100; 530/387.300; 530/287.700; 530/388.800; 530/388.850
NCLM: 435/069.700
NCLS: 435/070.210; 530/387.100; 530/387.300; 530/387.700; 530/388.800;
530/388.850; 536/023.100; 536/023.400
IC [6]
ICM: C12P021-04
EXF ICS: C07K016-00; C07H021-04
536/23.1; 536/23.4; 530/387.1; 530/387.3; 530/387.7; 530/388.1;
530/388.8; 530/388.85; 435/69.7; 435/70.21; 435/172.1; 435/172.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 41 OF 52 USPTFULT
AN 1998:64956 USPTFULT
TI Immunogenic cancer proteins and peptides and methods of use
IN Calenoff, Emanuel, Chicago, IL, United States
PA Northwestern University, Evanston, IL, United States (U.S. corporation)
PI US 5763164 19980809
AI US 1994-191338 19940203 (8)
RLI Continuation-in-part of Ser. No. US 1993-49698, filed on 16 Apr 1993,
now abandoned

DT Utility
FS Granted
LN.CNT 2928
INCL INCLM: 435/006.000
NCL INCLS: 435/005.000; 435/007.100; 435/007.200; 435/007.900; 435/069.100;
530/300.000; 530/388.100; 530/387.200; 530/350.000; 530/333.000;
530/403.000; 436/500.000; 436/548.000; 436/818.000; 424/001.110;
536/023.100
NCLM: 435/006.000
NCLS: 424/001.110; 435/005.000; 435/007.100; 435/007.200; 435/007.900;
435/069.100; 436/500.000; 436/548.000; 436/818.000; 530/300.000;
530/333.000; 530/350.000; 530/387.200; 530/388.100; 530/403.000;
536/023.100
IC [6]

ICM: C12N001-68
EXF ICS: G01N033-53; C07K015-28; C07H021-02
435/6; 435/5; 435/7.1-7.9; 435/69.1; 530/300; 530/388.1; 530/350;
530/387.2; 530/333; 530/403; 436/500; 436/548; 436/818; 424/1.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 42 OF 52 USPTFULT
AN 1998:61155 USPTFULT
TI Immunotherapeutic strategies for the treatment of cancer
IN Cohen, Edward P., Chicago, IL, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5759535 19980602
AI US 1994-242405 19940513 (8)
DT Utility
FS Granted
LN.CNT 963
INCL INCLM: 424/093.210
NCL INCLS: 435/172.300; 435/069.100; 435/320.100
NCLM: 424/093.210
NCLS: 435/069.100; 435/320.100
IC [6]
ICM: A61K048-00
EXP 514/44; 514/7; 435/172.3; 435/172.1; 435/240.1; 435/240.2; 435/320.1;
435/91.1; 424/93.21; 536/22.1; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 43 OF 52 USPTFULT
AN 1998:54484 USPTFULT
TI Monoclonal antibodies reactive with tumor proliferating cells
IN Morдох, Jose, Jose Hernandez 1837, Buenos Aires, Argentina 1426
De Cerone, Silvia, Simbon 4304, Buenos Aires, Argentina 1417
Podhajer, Osvaldo Luis, Ave. du General de Gaulle, Strasbourg, France
Bravo, Alicia Ines, Sanabria 3287, Buenos Aires, Argentina 1417
US 5753229 19980519
AI US 1994-335573 19941107 (8)
RLI Continuation-in-part of Ser. No. US 1994-285545, filed on 3 Aug 1994,
now abandoned which is a continuation of Ser. No. US 1994-185752, filed
on 21 Jan 1994, now abandoned which is a continuation of Ser. No. US
1991-766862, filed on 25 Sep 1991, now abandoned

DT Utility
FS Granted
LN.CNT 1688
INCL INCLM: 424/155.100
NCL INCLS: 424/174.100; 435/344.000; 435/070.210; 435/172.100; 530/388.800;
530/387.100
NCLM: 424/155.100
NCLS: 424/174.100; 435/070.210; 435/344.000; 530/387.100; 530/388.800
IC [6]
ICM: A61K039-395
EXF ICS: C12N005-10; C12N005-12; C07K016-30
435/70.21; 435/68.1; 435/172.1; 435/240.27; 435/344; 530/387.1;
530/388.8; 424/155.1; 424/174.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 44 OF 52 USPTFULT
AN 1998:39510 USPTFULT
TI Compositions and methods for delivery of genetic material
IN Carriano, Richard A., Paoli, PA, United States
Wang, Bin, Beijing, China
Weiner, David B., Merion, PA, United States
Apollon, Inc., Malvern, PA, United States (U.S. corporation)
The Trustees of the University of Pennsylvania, Philadelphia, PA, United
States (U.S. corporation)

PI US 5739118 19980414
AI US 1994-221579 19940401 (8)
DT Utility
FS Granted
LN CNT 3405
INCL INCLM: 514/044.000
INCLS: 514/025.000; 514/027.000; 514/033.000; 514/035.000; 514/054.000;
514/510.000; 514/580.000; 514/731.000; 514/732.000; 435/375.000;
435/069.100; 435/069.300; 435/172.100; 435/172.300; 424/278.100;
424/184.100
NCL NCLM: 514/044.000
NCLS: 424/184.100; 424/278.100; 435/069.100; 435/069.300; 435/375.000;
514/025.000; 514/027.000; 514/033.000; 514/035.000; 514/054.000;
514/510.000; 514/580.000; 514/731.000; 514/732.000
IC [6]
ICM: A61K048-00
ICS: C07H015-24; C12N015-64; C12N015-87
435/172.3; 435/69.1; 435/69.3; 435/375; 435/377; 514/44; 514/33; 514/35;
514/171; 514/27; 514/54; 514/510; 514/680; 514/731; 514/732; 514/25;
514/26; 424/278.1; 424/184.1; 935/52; 935/55; 935/56; 536/23.1;
536/23.5; 536/23.7; 536/23.72; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2002 ACS
AN 1997:499063 CAPLUS
DN 127:160563
TI Cellular proto-oncogene immunogens for cancer vaccines
IN Halpern, Michael S.; England, James W.
PA Allegheny University of the Health Sciences, USA; Halpern, Michael S.;
England, James W.
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725860	A1	19970724	WO 1997-US582	19970113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	NA	19970724	CA 1997-2241952	19970113
CA 2241952	A1	19970811	AU 1997-16992	19970113
AU 9716992	B2	20000323	EP 1997-902934	19970113
AU 9717356	A1	19990623		
EP 923284	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

JP 2001501909 T2 20010213 JP 1997-526124 19970113
US 6365151 B1 20020402 US 1998-167322 19981007
PRAI US 1996-10262P P 19960119
WO 1997-US582 W 19970113
US 1998-101226 B2 19980702

L13 ANSWER 46 OF 52 USPATFULL
AN 97:3820 USPATFULL
TI Genetic Immunization
IN Weiner, David B.; Meriton, PA, United States
Williams, William V.; Havertown, PA, United States
Wang, Bin, Havertown, PA, United States

PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)
The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5593972 19970114
AI US 1993-125012 19930921 (8)
RLI Continuation-in-part of Ser. No. US 1993-29336, filed on 11 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-8342, filed on 26 Jan 1993, now abandoned
DT Utility
FS Granted
LN CNT 3611
INCL INCLM: 514/044.000
INCLS: 424/278.100; 514/615.000; 514/818.000
NCL NCLM: 514/044.000
NCLS: 424/278.100; 514/615.000; 514/818.000
IC [6]
ICM: A61K045-05
ICS: A61K048-00; A61K031-00
435/320.1; 424/93.1; 424/93.2; 424/93.21; 424/278.1; 514/44; 514/615;
514/818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 47 OF 52 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 97064461 EMBASE
DN 1997064461
TI Biological principles and clinical development of prostate cancer gene therapy.
AU Sanda M.G.
CS Dr. M.G. Sanda, 2916 Taubman Center, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109-0330, United States
SO Seminars in Urologic Oncology, (1997) 15/1 (43-55).
Refs: 77
ISSN: 1081-0943 CODEN: SUONFC
CY United States
DT Journal: General Review
FS 016
022 Human Genetics
028 Urology and Nephrology
SL English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 96437043	A1	19961003	WO 1996-US582	19961003
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	NA	19961003	CA 1996-2241952	19961003
CA 2241952	A1	19970811	AU 1997-16992	19970113
AU 9716992	B2	20000323	EP 1997-902934	19970113
AU 9717356	A1	19990623		
EP 923284	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

JP 2001501909 T2 20010213 JP 1997-526124 19970113
US 6365151 B1 20020402 US 1998-167322 19981007
PRAI US 1996-10262P P 19960119
WO 1997-US582 W 19970113
US 1998-101226 B2 19980702

L13 ANSWER 48 OF 52 MEDLINE
AN 96437043 MEDLINE
DN 96437043 PubMed ID: 8839859
TI Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
AU Arvanitakis L; Meeri E A; Nador R G; Said J W; Asch A S; Knowles D M; Cesarman E
CS Department of Pathology, New York Hospital-Cornell Medical Center, New York 10021, USA.
NC A139192 (NIAID)
CA442710 (NCI)
EY06337 (NEI)

SO BLOOD, (1996 Oct 1) 88 (7) 2648-54.
Journal code: 7603509. ISSN: 0006-4971.
CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals; AIDS 19961
EM 19961
Entered STN: 19961219

Last Updated on STN: 19980206
Entered Medline: 19961107

L13 ANSWER 49 OF 52 USPAPFUL
AN 94:86325 USPAPFUL
TI Myod regulatory region
IN Tapscott, Stephen J., Seattle, WA, United States
Weintrub, Harold M., Seattle, WA, United States
Palmer, Theodore D., Kirkland, WA, United States
PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S.
corporation)
PI US 5352595 19941004
AI US 1991-753520 19910903 (7)
DT Utility
FS Granted
LN CNT 1777
INCL INCLM: 435/172.300
INCLS: 435/240.200; 435/320.100; 536/024.100
NCL NCLM: 435/006.000
NCLS: 435/320.100; 435/325.000; 435/354.000; 435/357.000; 435/456.000;
536/024.100
IC [5]
ICM: C12N005-10
ICS: C12N015-11; C12N015-85
EXF 435/172.3; 435/240.2; 435/320.1; 536/27; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L13 ANSWER 50 OF 52 USPAPFUL
AN 93:35475 USPAPFUL
TI Non-malignant cells coupled to adjuvants and their use in a method to
induce anti-tumor immunity
IN Eggers, Arnold E., New York, NY, United States
PA State University of New York (Sunny, Albany, NY, United States (U.S.
corporation)
PI US 5208022 19930504
AI US 1990-627555 19901210 (7)
RLI Continuation of Ser. No. US 1988-196037, filed on 19 May 1988, now
abandoned
DT Utility
FS Granted
LN CNT 600
INCL INCLM: 424/088.000
INCLS: 424/089.000; 424/090.000; 424/091.000; 424/092.000; 424/093.000;
530/402.000; 530/403.000; 530/404.000; 530/405.000; 530/406.000;
512/002.000; 435/240.100
NCL NCLM: 424/194.100
NCLS: 424/184.100; 424/193.100; 424/278.100; 424/279.100; 424/282.100;
435/357.000; 435/366.000; 512/002.000; 530/402.000; 530/403.000;
530/404.000; 530/405.000; 530/406.000
IC [5]
ICM: A61K039-00
ICS: A61K037-02
EXF 424/88; 424/95; 424/89; 424/90; 424/91; 424/92; 424/93; 530/402;
530/403; 530/404; 530/405; 530/406; 514/2; 435/240.1
L13 ANSWER 51 OF 52 MEDLINE
AN 92394695 MEDLINE
DN 92394695 Pubmed ID: 1521919
TI The H-ras oncogene regulates expression of 70- and 45-kDa
cell-surface molecules whose expression correlates with tumor-cell
immunogenicity.
AU Gopas J; Ehrlich T; Cohen O; Wisnialak O; Tainaky M A; Segal S;
Rager-Zieman B; Isakov N
CS Department of Microbiology and Immunology, Faculty of Health Sciences,

Ben-Gurion University of the Negev, Beer-Sheva, Israel.
SO INTERNATIONAL JOURNAL OF CANCER. (1992 Sep 9) 52 (2) 329-35.
Journal code: 0042124. ISSN: 0020-7136.
CY United States
LA English
FS Priority Journals
EM 199210
ED Entered STN: 19921023
Last Updated on STN: 1990129
Entered Medline: 19921013
L13 ANSWER 52 OF 52 MEDLINE
AN 89000486 MEDLINE
DN 89000486 Pubmed ID: 3262364
TI In vitro malignant progression of cells derived from Abelson murine
leukaemia virus-induced thymic lymphomas.
AU Saggiaro D; Zamarchi R; D'Andrea E; Chieco-Bianchi L
CS Institute of Oncology, University of Padova, Italy.
SO BRITISH JOURNAL OF CANCER. (1988 Aug) 58 (2) 152-7.
Journal code: 0370635. ISSN: 0007-0920.
CY ENGLAND: United Kingdom
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198811
ED Entered STN: 19900308
Last Updated on STN: 19970203
Entered Medline: 19881121

=>